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Peroxisome proliferators (PPs) are nongenotoxic carcinogens that produce a well-
characterized response in rodents including hepatomegaly, proliferation of peroxisomes,
dramatic induction of fatty acid metabolizing enzymes, and hepatocarcinogenesis. The
response is species-specific, with rats and mice being sensitive to both peroxisome
proliferation and carcinogenesis. Humans appear relatively insensitive to peroxisome
proliferation, but their susceptibility to PP-induced carcinogenicity is unknown. An initial
goal of this research was to determine if PPs are carcinogenic in rainbow trout, a species
that, like humans, has a limited peroxisome proliferating response. Three PPs were tested
for modulation of carcinogenesis. The adrenal steroid dehydroepiandrosterone (DHEA)
was a complete carcinogen and both DHEA and perfluorooctanoic acid enhanced aflatoxin
B1 (AFB 0-initiated hepatocarcinogenesis. Peroxisomal enzymes were not induced
indicating that carcinogenicity is independent of peroxisome proliferation. Additional
studies focused on three alternate mechanisms of DHEA carcinogenesis: genotoxicity,
intracrine effects, and enhancement of cell proliferation. Mutations of the Ki-ras gene are
rare in spontaneous tumors in trout; however, thirty percent of tumors examined from
DHEA-treated trout contained ras mutations. Some effects of DHEA may be mediated
through conversion into other hormones. A fluorinated DHEA analog, lacking the steroid
precursor properties of DHEA, was not carcinogenic and only slightly enhanced tumor
Redacted for Privacyincidence in AFB1- initiated trout. Finally, cell proliferation could be important in DHEA 
carcinogenesis. Treatment with DHEA causes dramatic increases in the percentage of body 
weight made up by liver. Histological examination indicates increases in liver somatic 
indices are due to both biliary cell proliferation and hepatocyte enlargement. Levels of 
proliferating cell nuclear antigen (PCNA), an index of DNA replication, were increased and 
levels of p53, a tumor suppresser protein involved in cell cycle regulation, were decreased. 
Tumor enhancement by DHEA was not limited to AFB i-initiated hepatocarcinogenesis. 
DHEA treatment of N-methyl-N'-nitro-nitrosoguanidine-initiated trout enhanced renal and 
hepatocarcinogenesis, but inhibited stomach and swim-bladder carcinogenesis. This 
research demonstrates that the carcinogenicity and tumor enhancing effects of DHEA are 
not limited to rodents and may occur through mechanisms independent of peroxisome 
proliferation. ©Copyright by Gayle A. Omer
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DEHYDROEPIANDROSTERONE SECRETION AND REGULATION
 
Dehydroepiandrosterone (DHEA, 5-androsten-313-01-17-one) is an adrenal steroid 
which, along with its sulfated ester (DHEAS) occur in extremely high levels in human 
plasma (Figure 1.1) (1). The secretion of DHEA, like cortisol is regulated by 
adrenocorticotropic hormone (ACTH) (2), however under some circumstances there are 
distinct differences in cortisol and DHEA secretion. 
HSO3 -O 
DHEA  DHEAS 
Figure 1.1.  Structures of DHEA and DHEAS. 
The functional role of DHEA is still unclear except that it serves as a precursor of 
other steroids. Adrenalectomy does not result in any particular symptoms of DHEA 
deficiency (3). During pregnancy, DHEAS secretion by the fetal adrenal gland followed by 
conversion to estrogens in the placenta provides considerable estrogen production (4). 
DHEA also serves as a precursor for both estrogens and androgens throughout life; adrenal 
steroids are an important source of estrogens in most postmenopausal women (5). 
DHEA and DHEAS are secreted in a pattern which varies according to age. Levels 
are low in children, but increase at puberty and peak during the second decade of life. The 
levels of DHEA and its sulfonated, glucuronidated, and fatty ester derivitives then decline 
with age (at a rate of about 6 mg DHEAS/dL/year). In both men and women, DHEAS 
levels of individuals in their 70's are about one-fifth those of people in their 20's and 30's 3 
(1, 6, 7). In men, DHEAS continues to decline after the age of 85, however in elderly 
women there is no further decrease (6). 
The reasons for the differences in DHEAS levels in populations of different ages is 
unknown. One possible explanation for lower DHEAS levels in older individuals is that 
DHEAS could be associated with higher mortality, leading to survival of individuals with 
low DHEAS levels. DHEAS has not been found to be associated with higher mortality, 
however (6). In addition, long term longitudinal studies in both men and women revealed 
decines in DHEAS with age in people studied for up to 13 years (8, 9). Therefore, the age-
associated decline in DHEAS appears to represent changes in individuals over time rather 
than the selection of individuals with low DHEAS levels. Although DHEA and DHEAS 
decline with age, serum cortisol remains relatively unchanged. Upon stimulation with 
ACTH, the adrenals produce less DHEA and DHEAS in elderly than in younger subjects, 
but the cortisol and androstenedione responses are similar in both groups (10). Nest ler et 
al. proposed that the decrease in DHEA/DHEAS may be the result of hyperinsulinemia 
which occurs in aging individuals due to increased insulin resistance and decreased insulin 
clearance (11). Insulin inhibits the activity of 17,20-lyase, the enzyme which converts 
17a-hydroxypregnenolone into DHEA, therefore insulin could decrease the production of 
these steroids (12). 
In addition to these age- and sex- differences, DHEA and DHEAS values are also 
highly variable within age groups (13). Several studies have been conducted to determine 
if lifestyles may affect these levels. Smokers were found to have higher levels of both 
DHEA (18% higher) and DHEAS (13% higher) than nonsmokers (14). Alcohol intake 
was also positively associated with serum DHEA levels in middle-aged men (14). In this 
study, dietary factors other than alcohol intake had little influence on the levels of serum 
hormones (14), however an association between vegetarian low fat diets and high DHEAS 
levels has been reported (15). Low levels of DHEAS have been found to correlate with 
obesity (16). Serum DHEAS levels were also reported to be higher in men over 45 and 4 
women of all ages who are practitioners of trancendental meditation (17). Obese men and 
women on low calorie diets excreted lower amounts of DHEA (18). 
Even after correcting for smoking and body mass index, DHEA was 58% and 
DHEAS was 45% lower in men over 64 years of age compared to men between 38 and 45 
(14). 
Most laboratory animals do not share such high levels of DHEA and DHEAS. It is 
only in humans and other primates that plasma levels of these adrenal steroids exceed those 
of all other hormones (19). Rabbits and dogs have an increase in DHEA and DHEAS 
upon reaching sexual maturity but the levels are still an order of magnitude lower than 
normal adult human values (19). Rat and mouse adrenals do not convert pregnenolone and 
progesterone into their 17-hydroxylated metabolites, leading van Weerden et al. (20) to 
conclude that rats and mice are not suitable models for research involving endogenous 
adrenal androgens. 
Like rodents, trout do not have high circulating levels of DHEA. A trout 313­
hydroxysteroid dehydrogenase 05-4-isomerase (313-HSD) has recently been cloned. When 
expressed in a mammalian expression system, this enzyme has high activity for the 
conversion of DHEA to androstenedione. This is in contrast to the rodent and human 313­
HSD which favor 17a-hydroxypregnenolone and pregnenolone as substrates. (21) 5 
CHEMOPROTECTIVE PROPERTIES OF DHEA
 
A nticarcinogenicity 
It is well documented that DHEA and DHEAS decrease markedly with age. Since 
cancer incidence rises during this same period, it is fascinating to speculate that the two 
events might be related. Considerable epidemiological evidence exists which suggests an 
association between low DHEA levels and certain cancers. Low levels of DHEA (and/or 
DHEAS) are associated with cancers of the stomach (22, 23), bladder (24), lung (25), and 
breast (26-29). Although most of these studies measured hormone levels after the clinical 
onset of cancer, there were several prospective studies as well. Prediagnostic levels of 
DHEA in serum of 13 individuals who subsequently developed gastric cancer (median time 
to diagnosis was 6.5 years) were 38% lower than in matched controls (22). Bulbrook et 
al. (26) measured urinary levels of adrenal androgen metabolites of 5000 healthy women 
from the island of Guernsey, Great Britain and then followed them clinically for up to nine 
years. In this study, the 27 patients who subsequently developed breast cancer were found 
to have had significantly lower prediagnosis adrenal androgen levels than matched controls. 
The association between low levels of DHEA and breast cancer may be limited to 
premenopausal breast cancer, however, as Zumoff et al. (29) showed that although 
premenopausal breast cancer patients had low plasma levels of DHEA and DHEAS, these 
steroids were higher than normal in postmenopausal breast cancer patients. These 
apparently contradictory findings may be explained by DHEA's dual role as a precursor of 
androgens or estrogens. In premenopausal women who normally have high estrogen and 
low androgen levels, DHEA may act to decrease the effects of estradiol by competing for 
binding for the estrogen receptor (directly or via estrogenic metabolites) (30). If DHEA 
levels are low, the risk of breast cancer in premenopausal women may be increased because 
the estradiol effect is unopposed. In postmenopausal women, however, the estrogenic 6 
effects of DHEA and its metabolites could lead to increased risk of breast cancer in women 
with high levels of DHEA (30). 
Breast cancer incidence varies considerably according to geographical location with 
a seven-fold higher incidence in certain Western countries compared to low incidence areas 
(31). Wang et al (32), examined plasma hormone levels in order to determine if the low 
incidence of breast cancer in Japanese women, compared to women in Western countries 
might be related to differences in endocrine function. In contrast to what would be 
expected if DHEA were having a protective effect, DHEAS levels were statistically higher 
in British than in Japanese women in all age groups examined (32). 
In animal models, DHEA has been shown to be protective towards a wide variety 
of cancers (see Table 1.1) including spontaneous, chemically induced, and virally induced 
cancers. 
Table 1.1. Prevention of carcinogenesis in animal models by DHEAa 
Species
Strain(s) 
Carcinogenb  DHEA Treatmentc  Target 
Organ(s) 
Reference(s) 
Mouse  None  450 mg/kg p.o.  Breast  (33, 34) 
C3H-A/A  3x/week 
C3H-AvY/A 
obese) 
Mouse  DMBA  0.6% dietary  Lung  (33, 35) 
Mouse  urethan  0.6% dietary  Lung 
A/J 
Mouse  DMH  0.6% dietary  Colon 
Balb/c 
(female) 
Mouse  DMBA  100.400 mg, applied to  Skin  (38) 
CD-1  skin 1 hr.  rior to DMBA 
Mouse  MCA  0.1% dietary  Uterus  (39)
 
Swiss Albino
 
Mouse  DMBA + TPA  100. 400 mg, applied to  Skin  (40)
 
CD-1  skin 1 hr.  rior to DMBA
 
Rat  DEN +  1% dietary  Liver  (41)
 
F344  partial  (preneoplastic
 
he  atectom  foci 
Mouse  DMBA  100. 400 mg. applied to  Skin  (38) 
CD-1  skin 1 hr.  rior to DMBA 7 
c 
Table 1.1. (continued) 
Mouse 
Swiss Albino 
Mouse 
CD -1 
Rat 
F344 
Rat 
F344 
Rat 
Rat 
Rat 
Sprague-Dawley 
Rat 
Wistar 
Rat 
F344 
Rat 
Sprague Dawley 
male 
Rat 
F344 
(male) 
Rat 
Sprague Dawley 
(male) 
DMBA + TPA 
DEN +
 
partial
 
he  tectom
 
DHPN
 
DMBA 
DEN+ AAF 
partial 
he s atectom 
MNU 
MNU+ 
testosterone 
DEN, MNU, 
BBN, DMH, 
DHPN 
DHPN 
azoxymethane 
i 
0.1% dietary 
100. 400 mg, applied to 
skin 1 hr. prior to DMBA 
1% dietary 
0. 6% dietary 
Silastic im . lants
 
0.6% dietary
 
120. 400 or 800 ppm
 
dietary
 
0.1% or 0.2%  dietary
 
0.3% dietary 
0.25% dietary (51 wks) 
0.6% dietary (starting 8 
wks after end of 
carcinogen) 
0.5% dietary 
1 
Skin 
Liver 
(preneoplastic foci) 
Liver 
(preneoplastic foci) 
Thyroid 
Breast 
Liver 
(preneoplastic foci) 
Breast 
Prostate 
thyroid, bladder, 
seminal vesicles 
(enhanced liver) 
Adrenal (focal 
lesions) 
Liver (GST-P 
positive foci) 
Colon (aberrant 
crypts) 
(39) 
(40) 
(41) 
(42) 
43 
(44) 
(45, 46) 
(47) 
(48) 
(49) 
(50) 
i  (51) 
i 
a  Modified from (52) 
b	  Abbreviations: 1,2-dimethylhydrazine (DMH), 7,12-dimethylbenz(a)anthracene 
(DMBA), 12-0-tetradecanoylphorbol-13-acetate (TPA), Diethylnitrosamine (DEN), 
dihydroxy-di-n-propyl-nitrosamine (DHPN), methylcholanthrene (MCA), N-
acetylamino-fluorine (AAF), N-methyl-N-nitrosourea (MNU), N-nitrosomorpholine 
(NNM). 
DHEA was administered during and subsequent to carcinogen exposure unless 
otherwise specified. 
DHEA has also been shown to be protective towards a number of in vitro cell 
transformation assays. DHEA blocks the conversion of 3T3 fibroblasts to adipocytes (53), 
and protects against aflatoxin Bi (AFB i) and DMBA-induced transformation of cultured 
embryonic hamster fibroblasts (54). 8 
Mechanisms of DHEA protection towards carcinogenesis 
DHEA is a powerful inhibitor of mammalian glucose-6-phosphate dehydrogenase 
(EC 1.1.1.49) (G6PD) (52, 55, 56). It has been proposed that the cancer chemoprotective 
effects of DHEA result from G6PD inhibition and subsequent depletion of NADPH and 
ribose-5-phosphate (37, 57, 58). This could inhibit carcinogenesis in a number of ways. 
NADPH is required for the function of cytochrome P450s, microsomal enzymes which 
metabolically activate many carcinogens. Lower NADPH levels could inhibit P450s and 
result in decreased metabolic activation of carcinogens. Ribose-5-phosphate is necessary 
for synthesis of deoxyribonucleotides and cell replication. Decreased cell proliferation and 
anti-promotional activity could result from the lower availability of deoxyribonucleosides 
(37). Evidence that G6PD is involved in the DHEA chemoprevention is provided by 
studies in which chemoprotective effects are reversed by supplementation with 
deoxyribonucleotides. Growth inhibition by DHEA of cultured He La TCRC-2 cells was 
reversed by supplementing the medium with deoxyribonucleosides (59). Treatment of rats 
with deoxyribonucleosides prevented the inhibition of DNA synthesis in liver preneoplastic 
tissues of DHEA-treated rats (60). Administration of ribonucleosides and 
deoxyribonucleosides prevented the DHEA-inhibition of enzyme altered foci in livers of 
rats initiated with DEN, treated with 2-AAF, and given a partial hepatectomy (60). 
Another potential chemoprotective effect of DHEA may also be dependent on G6PD 
inhibition. DHEA has been shown to inhibit the isoprenylation of ras p21 in vitro (61). 
Isoprenylation is one of a series of post-translational modifications necessary for membrane 
association and oncogenic activity of this protein. DHEA May act through depletion of 
intracellular pools of mevalonate, a precursor of both cholesterol and farnesyl -PPi and 
geranylgeranyl-PPi; which participate in isoprenylation reactions (61). The enzyme which 
catalyzes the formation of mevalonate, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) 
reductase requires 2 mol of NADPH for each mole of product produced (61). Inhibition of 
G6PD could result in decreased HMG-CoA reductase activity, depletion of mevalonate, 9 
and inhibition of isoprenylation (61). Exposure of HT-29 cells to DHEA resulted in 
growth inhibition and cell cycle arrest (at G1), effects which could be partially prevented by 
the addition of mevalonate to the culture medium (62). A recent study however, indicates 
that DHEAS may act to inhibit isoprenylation at a point in the mevalonate pathway 
subsequent to HMG-CoA reductase, possibly at the level of protein farnesyltransferase 
(63). 
Although G6PD inhibition by DHEA is readily demonstrated in vitro, several 
investigators have questioned its importance in the anticarcingenic process. G6PD activity 
was not inhibited in male Sprague-Dawley rats fed 0.6% DHEA for 16 days compared to 
pair-fed controls (64). Malic enzyme and isocitrate dehydrogenase activities were both 
increased by DHEA treatment, and cytoplasmic NADPH was not depleted (64). G6PD and 
ribulose-5-phosphate production were inhibited in female rats fed 0.6% DHEA for 15 
days, however NADPH levels were not decreased due to increases in isocitrate 
dehydrogenase and malic enzyme activity (65). Increased activity of malic enzyme has 
been demonstrated by several investigators (66, 67) and appears to compensate for any 
decreases in NADPH produced by G6PD inhibition. Increased malic enzyme activity may 
prevent the reduction of NADPH but does not counteract the decrease in ribose -5­
phosphate (65). In addition, certain cellular compartments may still experience a decrease 
in NADPH. 
A series of studies by Prasanna et al. (68-75), demonstrates that, even though there 
is decreased DNA binding of dimethylnitrosamine (NDMA), aflatoxin Bi (AFB1), and 
7,12-dimethylbenz(a)anthracene (DMBA) in livers of DHEA-fed animals, this decrease is 
not due to inhibition of metabolic activation. Instead both in vivo and in vitro studies 
suggest that DHEA enhances the metabolic activation of these compounds. Binding of 
metabolites to increased levels of hepatic protein may account for the decreased DNA 
binding in DHEA-fed animals. 10 
Other possible mechanisms of DHEA cancer chemoprevention include induction of 
glutathione-S-transferase (GST), inhibition of sulfotransferases, alterations in cytochrome 
P450 profiles, and inhibition of nitric oxide generation. Dietary DHEA induces a mouse 
GST (subtype GT-8.7) (76). This is the GST isozyme induced in mouse liver by 
antioxidants (77). GST induction is a common mechanism of cancer chemoprevention in 
rodents, although its relevance in humans is not yet known. Sulfation can be an activation 
pathway for certain carcinogens such as 7,12-dihydroxymethylbenz[a]anthracene and 6­
methylbenzo[a]pyrene which can form electrophilic sulfuric acid ester metabolites (78, 79). 
DHEA is a potent inhibitor of hepatic sulfotransferase activity and may be protective 
towards carcinogens which are activated in this manner. In addition to its possible effects 
on cytochrome P450s through NADPH depletion, DHEA may also modify the profile of 
P450s. DHEA is a peroxisome proliferator and induces the activity of cytochromes 
P4504A (80). DHEA may reduce the formation of reactive metabolites through alterations 
in cytochrome P450s (81). Recently it was reported that DHEA and its structural analog 
inhibit nitric oxide generation in response to lipopolysaccharide and interferon gamma in 
macrophages (82). There are also some additional properties of DHEA such as hormonal 
effects which may be important in certain cancers. DHEA's cancer chemoprotective 
properties may also be closely linked to its effects on other diseases. 
Immunoprotection 
In addition to DHEA's chemoprotective effects towards cancer, this compound has 
been shown to enhance the immune response in a variety of animal models. DHEAS 
treatment prevented spontaneous interleukin-6 (IL-6) production in aged mice (83). IL-6 is 
a cytokine involved in a wide variety of responses including the immune response, the 
acute phase response, osteoclastogenesis and hematopoiesis. Unregulated production of 
IL-6 may be involved in many chronic inflammatory conditions and infectious processes 
(3) and may be a consequence of aging as plasma levels are increased in the elderly and in 11 
numerous diseases of old age (84). DHEA treatment of burned mice allowed them to 
maintain resistance to Listeria infection and prevented a prolonged IL-6 response (85). 
Some of DHEA's immunoprotective effects may be due to its antiglucocorticoid effects. 
DHEA stimulated T cell proliferation and IL-2 production in animal models and prevented 
dexamethasone-induced thymic involution in mice (86). DHEA provided protection 
towards lethal viral and bacterial infections in C57BL/6J mice challenged with herpes 
simplex type 2 virus (HSV2), human diabetogenic coxsackievirus B4 (CVB4), or 
Streptococcus faecallis (87). A single dose of DHEA (100 mg/kg) reduced mortality from 
95% to 24% in CD-1 mice treated with a lethal dose of lipopolysaccharide (endotoxin) 
(88). The dramatic effects of DHEA on immune function in animals led to interest in the 
use of DHEA for disorders of the human immune system including lupus, multiple 
sclerosis, and HIV. 
DHEA had mixed effects on cell-mediated immune function in healthy 
postmenopausal women treated for three weeks with 50 mg/kg DHEA. Subjects had 
enhanced natural killer cell activity and decreased IL-6 production, however CD4+ (helper) 
T-cells were decreased (89). 
An open-labeled noncontrolled study was conducted in which ten patients with 
systemic lupus erythematosus were treated with 200 mg DHEA/day. DHEA was well 
tolerated with the exception of some acneiform dermatitis and appeared to provide some 
benefits to the patients (90). The improvements may have been the result of increased 
androgens (testosterone levels were increased about 8-fold).  Alternatively they could be 
due to alterations in cytokine secretion (91). 
Multiple sclerosis (MS) is another disease for which DHEA treatment is being 
examined. The etiology of this neurological disorder is still unclear, however an altered 
immune response may be involved. Ten of 21 MS patients treated with 90 mg DHEA/day 
for 14 weeks reported benefits including increases in energy, sexual performance, and 
mental alertness although there were no significant improvements noted on the Kurtzke 12 
numerical scale (92). In another uncontrolled study, 17 MS patients were given 40 
mg/kg/day DHEA for up to three months. Hirsutism and voice changes occurred in some 
patients. No improvements in motor or sensory symptoms occurred, however relief from 
fatigue was experienced by 64% of the patients (93). 
Plasma levels of DHEA are reduced in individuals infected with human 
immunodeficiency virus (HIV) (94, 95). The levels of DHEA can be used to predict 
progression from an asymptomatic stage to autoimmunodeficiency syndrome (AIDS) (96). 
In AIDS and other chronic infections, there are high circulating levels of cytokines 
including tumor necrosis factor-alpha (TNFa) and IFNa (97). Both TNFa and IFNa 
inhibit conversion of DHEAS to DHEA in mouse macrophages (therefore cellular activation 
results in down-regulation of macrophage metabolism of DHEA to DHEAS) (98). It has 
been suggested that the usefulness of thalidomide in the treatment of leprosy and HIV 
infections could be through inhibition of TNFa and subsequent restoration of DHEAS 
metabolism (98). DHEA itself, however, decreases macrophage production of TNFa 
(88), therefore the lower circulating levels of DHEA could either result from, or be the 
cause of the increases in TNFa. 
In vitro, DHEA has been shown to inhibit both wild-type and 3' azido-3' 
deoxythymidine (ALF)-resistant HIV-1 (99). DHEA inhibits HIV-1 replication in human 
lymphocytes and macrophages (100). One mechanism through which DHEA is believed to 
act against HIV is similar to that proposed for cancer chemoprevention, that is through 
inhibition of G6PD and reduction of ribonucleosides necessary for virus replication (99). 
DHEA has also been shown to interfere with the action of NF-kB binding protein, a 
transcription factor which up-regulates HIV-1 gene expression (101) . 
Clinical trials are in progress to test the effectiveness of DHEA in the treatment of 
AIDS. A phase 1 clinical trial has already been conducted to evaluate safety and 
pharmacokinetics. Thirty-one patients with mild symptomatic HIV were treated with up to 
2,250 mg DHEA/day for 16 weeks. The subjects are reported to have tolerated these doses 13 
well, however the limited immunological evidence collected in this study was mainly 
negative (102)  . 
A ntiaging 
Declining levels of DHEA and its sulfate ester are among the physiological changes 
which accompany aging in humans (1). There is considerable interest in the possibility that 
DHEA might reverse the aging process and allow people to age well and live longer. 
Some evidence supports these claims. A large cross-sectional epidemiological 
study sponsored by the MacArthur Foundation Research Network on Successful Aging, 
compared a group of 1192 high functioning) elderly men and women with medium and 
low functioning age- and gender-matched groups (103). DHEAS levels in the high-
functioning group were 44% higher than in the low-functioning group (p  0.001). 
In contrast, however a large prospective study in which baseline DHEAS levels 
were measured 16 years prior to a series of cognitive tests, failed to find any association 
between DHEAS levels and cognitive function in old age (104). There were also no 
significant difference in DHEAS levels between 16 individuals suffering from Alzheimer's 
disease and 53 with intact cognative function in elderly subjects, aged 85 and over (6). 
Several studies have administered DHEA to older adults. In one, DHEA was 
administered at 50 mg/day for six months to men and women ranging from 40 to 70 years 
of age. This treatment restored DHEA and DHEAS levels to the levels of young adults and 
increased serum androgens about 2-fold in women subjects. The most significant finding 
was that DHEA treatment resulted in increases in perceived physical and psychological 
well-being (105). 
1 Individuals were classified into functional groups based on both physical (gait, balance, 
and muscular strength) and cognitive (a battery of memory and language tasks) tests. 14 
Cardiovascular 
The reported effects of DHEA on cardiovascular function are mixed with distinct 
sex differences. A strong age-independent inverse correlation between DHEAS levels and 
mortality from cardiovascular and ischemic heart disease in men was reported by Barrett-
Connor et al., in 1986 (106). In this prospective study, an increase of 100 mg/dL in 
plasma DHEAS was associated with a 48% reduction in mortality from cardiovascular 
disease after adjusting for age, blood pressure, cholesterol, smoking status, etc. A 
followup study confirmed these results in men, but found markedly different effects in 
women in which those with the highest levels of DHEAS had the highest rates of mortality 
from cardiovascular disease (107, 108). The reason for the sex-related differences is 
unknown, but may (as appears to be the case with breast cancer) be dependent on the 
hormonal environment. In men, DHEA may be acting as an estrogen and protect against 
cardiovascuar disease, while in women, its conversion into androgens may increase the 
risk (30). 
A slight inverse association between DHEAS and coronary artery disease (CAD) in 
men was also observed by Contoreggi et al. (109) (p = 0.06), however it was quite weak 
compared to the strong relationship between cholesterol or systolic blood pressure and 
CAD  .  The difference might be due to the fact that the Barrett-Connor studies were limited 
to cardiovascular disease resulting in mortality while this study looked at non-fatal cases as 
well. A third large scale longitudinal study found lower age-adjusted DHEAS levels in 
individuals who subsequently developed fatal coronary heart disease but no differences 
between cases of nonfatal myocardial infarction and controls (110). 
In the Helsinki Heart Study, treatment of dyslipidemic middle-aged men with 
gemfibrozil produced favorable changes in plasma lipoproteins and reduced the incidence 
of coronary heart disease (111). A nonsmoking subset of this population was examined 
and found to have increased serum DHEA, DHEAS, androstenedione, androstanediol 
glucuronide, and cortisol compared to placebo-treated controls (112). It is possible that the 15 
effects of fibrate drugs on lipid metabolism are mediated through pituitary-adrenocortical 
function and androgen metabolism (112). 
Population studies, however, do not support the idea of an inverse association 
between DHEAS and coronary heart disease (110). Of three populations reported in the 
literature, DHEAS levels were highest in white Californian men (106), intermediate in 
Japanese men living in Honolulu (110), and lowest in Japanese men residing in Japan 
(113). Coronary disease rates follow the same pattern with Californian males having the 
highest levels of heart disease and Japanese males the lowest. This is the opposite of what 
would be expected if DHEAS were protective towards heart disease. 
Animal studies provide some evidence that DHEA may protect against 
atherosclerosis. In New Zealand White rabbits which had atherosclerosis induced by aortic 
balloon catherization and a high cholesterol diet (2%) atherosclerotic plaque size was 
reduced by almost 50% by DHEA feeding (114). In another study, dietary DHEA 
inhibited fatty streak formation in cholesterol-fed rabbits by 30 to 40% independent of 
plasma cholesterol levels (115). 
Antiobesity 
DHEA's effects on energy metabolism have been extensively studied (reviewed in 
(116, 117)). Studies in mice (118), rats (119), and dogs (120) all demonstrated that 
DHEA reduced body fat without affecting caloric intake. Most of the weight difference in 
mice was from lower triacylglyerol content, possibly through decreased lipogenesis (118). 
Weight loss also occurred in the obese Zucker rat, however in this model 
differences in food consumption were noted between lean and obese animals. In lean 
animals, caloric intake increased with DHEA treatment, but in obese animals, food intake 
was lower in DHEA-treated animals, indicating that DHEA's effects on obesity may be due 
in part to appetite suppression (121). At high (0.3-0.6% ), but not at low doses, energy 
intake appears to be altered by taste aversion. Non-oral DHEA also altered energy intake 16 
however, indicating that effects of DHEA on obesity are not simply due to taste aversion 
(122). 
Several clinical trials have been conducted in humans. In normal men given high 
doses of DHEA (1600 mg/day) for 4 wks, a remarkable 31% decrease in body fat was 
reported (123). When administered to obese males for the same length of time, however 
there were no effects on total weight, body fat mass, fat distribution, or lipid status (124). 
Other researchers failed to find any differences in body weights, lean body mass, metabolic 
rate, leucine flux, or rate of incorporation of leucine into muscle protein in normal males 
given 1600 mg/day for 4 weeks (125). This study utilized a double blind crossover study 
in which subjects were all treated with the drug for four weeks, either in the first or second 
phase of the study as compared to the design in the Nest ler, 1988 paper where subjects 
were assigned to either a DHEA or placebo group but no crossover was conducted (123). 
Diabetes 
Lower levels of DHEAS have been found in men who subsequently were treated 
for diabetes (110). Treatment of obese Zucker rats with 6000 ppm DHEA for 5 weeks 
decreased serum insulin levels without altering insulin resistance or changing pancreatic 
insulin levels (126). Dietary DHEA had marked therapeutic effects in mutant mice with 
diabetic-obesity syndromes,including reducing blood sugar levels to normal, preventing 
islet atrophy, and sustaining insulin levels (127). It has recently been shown, however, 
that mice with this mutation also express a unique sulfotransferase with considerably 
different kinetic properties than the enzyme in control mice (128). This model, therefore 
may not be appropriate for studies on DHEA and diabetes. 
Adult human males (normal or obese) treated with 1600 mg DHEA/day did not have any 
changes in tissue sensitivity to insulin (123, 124). 17 
ADVERSE EFFECTS OF DHEA
 
DHEA, however, has several properties that limit its use as a chemopreventive 
agent. It is a precursor for androgens and estrogens and in human clinical trials has been 
shown to increase androgen levels in female subjects (105, 129). In the rat, DHEA 
stimulates androgen dependent gene expression and increases ventral prostate weight 
probably through its conversion into dihydrotestosterone (DHT) (130). Growth of 
implanted prostate carcinomas in castrated rats was greatly enhanced by DHEAS treatment 
(131) (Table 1.2). This contrasts with a study listed in Table 1.1 in which DHEA protected 
towards prostate cancer in rats (47). In that study, however prostate cancer growth was 
promoted with testosterone. In the presence of high levels of androgens, DHEA probably 
would function as an estrogen and be protective. In the absence of testosterone, however, 
the androgenic effects of DHEA prevail and prostate cancer is enhanced. The contribution 
of adrenal androgens to prostate cancer growth has important clinical implications for 
human prostate cancer patients. Because 5-10% of circulating androgens are of adrenal 
origin, therapy which inhibits only androgens of testicular origin may not be effective 
(131). 
In addition to being a steroid precursor, DHEA is also a peroxisome proliferator 
(80, 132, 133) and rodent carcinogen (134) (Table 1.2). Peroxisome proliferators (PPs) 
are a class of nongenotoxic carcinogens which produce a well characterized response in 
rodents including increases in size and numbers of the cellular organelles known as 
peroxisomes, dramatic induction of peroxisomal and microsomal enzymes involved in lipid 
metabolism, and liver enlargement as well as hepatocarcinogenicity (135).There is 
considerable human exposure to peroxisome proliferators as many common chemicals 
produce this response. Some of the agents which induce peroxisome proliferation include 
hypolipidemic drugs such as clofibrate (CLOF), phenoxyacetic acid herbicides, plasticizers 
such as diethylhexylphthalate (DEHP), perfluronated fatty acids, and nonsteroidal 18 
Table 1.2. Enhancement or mixed effects towards carcinogenesis by DHEA 
Species i Carcinogen  1 DHEA Treatment  Target Organ(s) 1 Reference(s) 
Strain(s)  i  i 1 
Rat  i BBN +BHA  .  0.6% dietary  Forestomach  [ (136) 
F344  i  (Bladder cancer was 1 i 
I i inhibited 
Mouse  i 0.4% dietary  Ovaries  (137) I None 
SWXJ-9  i or silastic capsules of 10 
1  mg. 
Rat  1 AZA  10.6% dietary (acetate)  Pancreas  (138, 139) 
Lewis 
1 Rat 
1 i DMN  0.6% dietary  Kidneys  (140) 
Wistar 
Rat  1 R3327 prostate  1 22.5, 16.8, 11.2 mg/wk  Prostate  (131) 
Fisher/  i  1 Sub. Q I carcinoma implant 
Copenhagen  _.1  DHEAS 
Rat  None  i 0.5 %  Liver  (134) 
F344  i 1% die .  (78wks) 
i 
Rat  DHPN  1 0.6% (during initiation  Lung  (141) 
F344  1 phase only)  (Liver foci 
inhibited) 
Hamster  DHPN +  Liver (GST-P foci)  (42) 
Syrian golden  Opisthorchis 
infestation 
Rainbow Trout  None  222, 444  888 ppm  Liver  Chapt. 3,5, '  Mt. Shasta  I dietary (7 months) 
Rainbow Trout  AFB I  155 -888 ppm dietary  Liver  1 Chapt. 3,5,6 
Mt. Shasta 
Rainbow Trout  MNNG  11 55-888 ppm dietary  Liver  1 Chapt. 7 
Mt. Shasta  Kidney  i 
1 
(Stom. and Swim  I 
Bladder inhibited) 
Abbreviations: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), butylated hydroxyanisole 
(BHA), azaserine (AZA), dimethylnitrosamine (DMN), aflatoxin B1 (AFB1), N-methyl­
N'-nitro-nitrosoguanidine (MNNG), dihydroxy-d-n-propylnitrosamine (DHPN) 
antiinflammatory agents (142). Most of the effects of peroxisome proliferators are believed 
to be mediated through peroxisome proliferator activated receptors (PPARs). PPARs are 
nuclear hormone receptors belonging to the same class of receptors as the vitamin D, 
thyroid hormone, and retinoic acid receptors as well as several orphan receptors (143). 
Like other nuclear hormone receptors, PPARs are zinc finger proteins that bind to specific 
response elements on genes such as the acyl CoA oxidase gene. PPARs appear to bind as 
a heterodimer with the retinoic acid receptor (144). Three PPARs (a, (3, and y) have been 19 
cloned from Xenopus, one from mouse, one from rat, and one from human (145), The 
protein sequences of these share a high degree of homology, particularly in the DNA-
binding domain. 
In addition to enzymes involved in lipid metabolism, malic enzyme has also been 
shown to be regulated by the PPAR, as a PPRE has recently been characterized for this 
enzyme (146). This is the first example of a gene regulated by PPAR which is not directly 
involved in fatty acid oxidation. Peroxisome proliferators may also have effects which are 
independent of the PPAR. Certain peroxisome proliferators (fibrates) down regulate 
transcription of apoA-1 in a manner which appears to be independent of the PPAR (147). 
DHEA, like most other peroxisome proliferators is nongenotoxic in short-term 
mutagenicity assays. DHEA was negative in the Ames Salmonella mutagenicity (spot test) 
(148), sister chromatid exchange (149), and rat primary hepatocyte unscheduled DNA 
synthesis assays (150). In an in vitro DNA binding assay, however, DHEA was 
metabolically activated to a form which bound to DNA and protein (74). 
Treatment of rats and mice with DHEA produced the characteristic response of 
peroxisome proliferators including increases in size and number of peroxisomes, levels and 
activity of P4504As, peroxisomal B-oxidation activity, levels of the peroxisomal 
bifunctional enzyme, catalase activity, and liver weight (67, 80, 132, 133, 151-157). 
Although DHEA produces the same spectrum of responses as other peroxisome 
proliferators, DHEA has some important differences. DHEA does not appear to be able to 
activate the PPAR (158, 159). In addition, DHEA lacks the carboxylic acid group common 
to most peroxisome proliferators (160). There is some evidence that the sulfate conjugate 
of DHEA is the active peroxisome proliferator (161), however this compound is also 
unable to activate the PPAR (158, 159). DHEA and DHEAS appear to bind specifically to 
certain cytosolic proteins (162, 163). It is possible that DHEA is acting through a separate 
signal transduction pathway than other PPs. The differences between DHEA and other 20 
peroxisome proliferators may aid in the determination of the mechanism of peroxisome 
proliferator induced carcingenesis. 
There are dramatic species difference in the response to peroxisome proliferation 
(164, 165). Rats and mice are highly responsive, whereas, primates are relatively resistant. 
The mechanism through which these nongenotoxic carcinogens produce liver tumors is 
unknown, but may involve the formation of a prooxidant state (166), stimulation of cell 
proliferation (167-169), or alterations in signal transduction (170, 171). If the 
carcinogenicity is directly related to peroxisome proliferation, then these compounds may 
pose little risk to humans because primates are fairly resistant to this response. The 
carcinogenicity may be due to mechanisms independent of peroxisome proliferation, 
however. Rainbow trout may prove to be appropriate models for the study of peroxisome 
proliferators. Like primates, trout appear to be weak responders to peroxisome proliferation 
(172-175). 
Several different approaches have been used to minimize the adverse side effects of 
DHEA treatment. A DHEA formulation has been developed which places micronized 
DHEA within a lipophilic matrix (176). The authors suggest this delivery method should 
decrease conversion of DHEA to more potent steroids by minimizing the hepatic first-pass 
effects. Postmenopausal women administered a single 150 or 300 mg dose of oral 
micronized DHEA had 4- and 7-fold higher serum testosterone levels than placebo 
controls, however these values were still within the normal range of testosterone in 
premenopausal women. Serum DHEA was induced 7- and 12-fold by these same doses 
(176). 
One of the eight individuals paticipating in this study had elevated liver enzymes at 
the conclusion of the study and developed clinical hepatitis 2 weeks later (176). The 
antinuclear antibody titers were present prior to the experiment, however this does not 
eliminate the possibility that DHEA could have enhanced the development of the condition . 
Considering what is known about DHEA effects on the livers of laboratory animals, this is 21 
a rather disturbing side effect and should not be dismissed lightly, especially since DHEA 
is being considered for long-term clinical trials. 
Another approach to decrease the toxic side effects of DHEA treatment has been the 
development of structural analogs lacking these adverse effects. 3B-methylandrost-5-en­
16 -one (DE-7) is a synthetic steroid in which the 3B-hydroxyl group is replaced by a 
methyl group, a modification which minimizes the conversion to androstenedione (37). 
DE-7 is not estrogenic (according to the rat uterotropic assay) and has enhanced 
chemoprotective properties towards skin cancer (40). DE-7 is also considerably more 
effective than DHEA as an antiobesity and antidiabetic agent in laboratory animals (38). 
16a-fluoro-5-androsten-17-one (8354) and 16a-fluoro-5a-androstan-17-one (8356) are 
fluorinated DHEA analogs that are more potent than DHEA as inhibitors of G6PD but 
which lack the peroxisome proliferating, androgenic, and estrogenic effects of DHEA 
(177). Compound 8354 is considerably more effective than DHEA as an antiobesity agent 
in mice (177). DHEA analogs 8354 and 8356 are more effective than DHEA in blocking 
12-0-teu-adecanoylphorbol-l3-acetate (TPA) stimulation of prostaglandin E2 in mouse 
epidermis (177). Analog 8354 is a stronger inhibitor of HIV-1 latency reactivation in 
ACH-2 cells stimulated by TPA than DHEA (101).  These structural analogs show 
considerable promise as chemopreventive agents. Certain chemopreventive properties of 
DHEA, however may be due to its conversion into androgens and estrogens. For these 
conditions, the analogs will probably not be beneficial. 22 
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ABSTRACT
 
Three structurally diverse peroxisome proliferators, clofibrate (CLOF), 
dehydroepiandrosterone (DHEA) and perfluorooctanoic acid (PFOA), were tested in the 
trout tumor model as complete carcinogens or enhancers of aflatoxin Bi (AFB1)-initiated 
hepatocarcinogenesis. Dietary exposure of trout for seven months demonstrated that only 
DHEA (0.18%) was a complete carcinogen. The effects of these compounds on AFBi 
carcinogenesis were mixed and dependent on dose. Dietary DHEA or PFOA at 1800 ppm 
significantly enhanced the incidence, multiplicity and size of liver tumors in AFB1- initiated 
trout, the predominant type of tumor being either mixed carcinoma or hepatocellular 
carcinoma. Lower doses of PFOA (222-888 ppm), however, did not enhance 
carcinogenesis, instead they provided some protection. High doses of CLOF (1800-4400 
ppm) inhibited AFB1- initiated hepatocarcingenesis while lower doses (111 444 ppm) of 
CLOF had no effect on tumor incidence. The highest doses of CLOF produced a shift in 
tumor type to predominantly cholangiocellular carcinomas. The maximal induction of 
peroxisomal 13-oxidation was less than two-fold, confirming previous observations that trout 
are relatively insensitive to peroxisome proliferators. Therefore, the tumorigenic properties 
of DHEA and the tumor promoting activities of DHEA and high doses of PFOA in trout 
appear to be independent of peroxisome proliferation. 39 
INTRODUCTION 
Peroxisome proliferators comprise a set of structurally diverse chemicals which 
elicit a similar spectrum of biochemical and pathological alterations including hepatomegaly, 
increased numbers of peroxisomes, induction of enzymes involved in the B- and co­
oxidation of fatty acids in peroxisomes and microsomes, respectively and 
hepatocarcinogenesis in rodents upon prolonged exposure (1-4). The mechanism of 
enzyme induction involves activation of a specific receptor, the peroxisome proliferator­
activated receptor (PPAR), which binds to specific response elements in 5'-flanking regions 
of inducible genes (5). 
A marked species difference in sensitivity to peroxisome proliferation has been 
documented (6, 7). Rats and mice are highly responsive, whereas, primates are relatively 
resistant. The mechanism through which these nongenotoxic carcinogens produce liver 
tumors is unknown, but may involve the formation of a prooxidant state (8), stimulation of 
cell proliferation (9, 10), or alterations in signal transduction (11, 12). If the carcinogenicity 
is directly related to peroxisome proliferation, then these compounds may pose little risk to 
humans because primates are fairly resistant to this response. The carcinogenicity may be 
due to mechanisms independent of peroxisome proliferation, however. 
One way to determine if peroxisome proliferators pose a risk to human health is to 
test them for carcinogenicity in species that resemble humans in their response to these 
compounds. Rainbow trout may prove to be appropriate non-rodent models for the study of 
peroxisome proliferators. Ciprofibrate treatment of rainbow trout induced peroxisome 
proliferation, causing increases in peroxisomal volume, peroxisomal bifunctional enzyme 
and catalase levels, and acyl-CoA oxidase activity (13). The response was minimal, 
however, compared to rodents with doses that produce 10-fold increases in peroxisomal B-
oxidation in rats causing less than a 2-fold increase in trout (14). Trout appear to be similar 
to primates in their response to peroxisome proliferators (13). 40 
We selected three representative peroxisome proliferators for study in the trout. 
Clofibrate (CLOF) is a hypolipidemic drug, which has been shown to be a complete 
hepatocarcinogen in rodents (15, 16). Perfluorooctanoic acid (PFOA) is one of a group of 
perfluorinated fatty acids widely used in hydraulic fluids, corrosion inhibitors, heat 
exchangers and water repellents (17). PFOA has been found to increase the incidence of 
malignant hepatocellular carcinomas in diethylnitrosamine-initiated rats (18). 
Dehydroepiandrosterone (DHEA) has been classified as a peroxisome proliferator but 
differs structurally and functionally and is the only peroxisome proliferator which does not 
appear to activate the PPAR (19-21). DHEA is a C19 steroid produced by the adrenal of 
humans in a pattern characterized by rising plasma levels (predominantly as the sulfate) early 
in life, peaking at 25 years of age with subsequent declines (22). Plasma levels of DHEA-
sulfate in humans appear to be inversely correlated to the risk of developing some cancers 
(23). Animal studies have documented chemopreventive properties of DHEA toward 
atherosclerosis, diabetes, obesity and cancer (24-26). The anticarcinogenesis properties of 
DHEA are still being actively investigated, but may be due to inhibition of glucose -6­
phosphate dehydrogenase and NADPH depletion (25). In contrast to its anticarcinogenic 
properties, however, prolonged administration of DHEA to rodents results in 
hepatocarcinogenesis (27). The phenotypic expression of various enzymatic markers in 
tumors of DHEA-treated rats differs from tumors initiated by genotoxic agents and 
resembles tumors produced by other peroxisome proliferators (28). 
The studies reported here examine tumor modulation by these three peroxisome 
proliferators in the trout. Both PFOA and DHEA, when fed at 1800 ppm significantly 
enhanced the incidence and multiplicity of tumors in aflatoxin Bi (AFB1)-initiated trout. In 
addition, DHEA was a complete hepatocarcinogen in sham-initiated trout. At high doses, 
CLOF inhibited hepatocarcinogenesis in AFB1- initiated trout and altered the predominant 
tumor type from mixed carcinoma to cholangiocellular carcinoma. 41 
MATERIALS AND METHODS
 
Chemicals 
DHEA, NAD+, palmitoyl CoA, FAD, dithiotreitol, and coenzyme A were 
purchased from Sigma Chemical Co. (St. Louis, MO). CLOF and PFOA were from Fluka 
Chemika (Switzerland). Potassium cyanide was purchased from Mallinckrodt (Paris, 
Kentucky). 
Animals and diets 
Two separate tumor experiments are described in this chapter. In each, Mt. Shasta 
rainbow trout (Oncorhynchus mykiss) were spawned and raised in our laboratory, then 
were initiated as fry (10 weeks post-hatch) by immersion in 0.01 ppm AFB1 for 30 min. 
Control trout were sham-exposed to vehicle (0.01% ethanol) alone. The trout were fed 
modified Oregon Test Diet (OTD) (29) containing 100 ppm vitamin E for 3 months, 
following which the experimental diets were fed for 30 weeks until the termination of the 
study. In the first experiment, five different experimental diets were fed to AFBrinitiated 
or control trout. CLOF was fed at either 0.18 or 0.44% (wet weight). The high dose of 
dietary CLOF was initially 0.72% but had to be reduced after 2 weeks due to food refusal. 
PFOA was fed at either 0.02 or 0.18%, and DHEA was fed at a single dietary dose of 
0.18%. In the second experiment, trout were fed 0, 111, 222, or 444 ppm CLOF; 222, 
444, 888, or 1108 ppm PFOA; or 55, 111, 222, 444, or 888 ppm DHEA. The diets were 
made up in batches of two kg and stored at -20°C until used. Trout were killed after thirty 
weeks on experimental diets by an overdose of tricaine methanesulfonate anesthetic 
(MS222) and livers removed, weighed, examined grossly and stored in fixative (Bouin's 
solution) until tumors could be confirmed and classified histologically as described by 
Hendricks (30). 42 
Enzyme  Assays 
Peroxisomal enzyme activities were measured after 29 (experiment 1) or 27 
(experiment 2) weeks on experimental diets. Livers were removed, weighed, and placed 
into ice cold homogenization buffer (60 mM tris, 0.25 M sucrose buffer, pH 8.3). They 
were homogenized, centrifuged at 600 g for 20 min (4°C) to pellet cell debris and nuclei, 
and the supernatant centrifuged at 12,000 g (4°C) for 30 min to obtain the 
mitochondrial/peroxisomal fraction. This fraction was resuspended in homogenization 
buffer and protein concentration determined by the method of Lowry et al., using bovine 
serum albumin as a standard (31). Peroxisomal 13-oxidation was assayed by 
spectrophotometrically monitoring the reduction of NAD+ to NADPH in the presence of 
palmitoyl CoA and cyanide (32, 33). Catalase activity was measured by following the 
decomposition of hydrogen peroxide at 240 nm (34). 
Statistical analysis 
The effect of dietary peroxisome proliferators on tumor incidence was analyzed by 
logistic regression analysis using SAS (Sas Institute, Cary NC). Tumor multiplicity data 
was analyzed by the Kruskal-Wallis test with p-values based on the exact permutation 
distribution (StatXact). The average log tumor size was compared using one-way analysis 
of variance (ANOVA) followed by Dunnett's test using both weighted and unweighted 
analyses (with identical conclusions). The effects of peroxisome proliferators on liver 
weight and I3-oxidation were analyzed with SAS using one-way ANOVA followed by the 
Scheffe test for establishing significant differences between control and experimental 
treatments. 43 
RESULTS
 
Experiment I 
In the preliminary study, diets containing 0.18% DHEA or PFOA significantly (p < 
0.0001) enhanced the incidence of liver tumors in AFB1- initiated trout (Fig. 1). The 
enhanced tumor yield was especially striking in the DHEA-fed trout, as 100% of these 
animals had tumors. In addition, the multiplicity increased significantly (p < 0.0001) in 
both DHEA- and PFOA-fed trout (Fig. 1). The majority of DHEA-treated trout had six or 
more tumors per liver compared to one or two tumors per liver in tumor-bearing control 
animals. Tumors in the DHEA-fed group were also larger (p < 0.0001) than in the control 
AFB1- initiated group (data not shown). 
The results of post-initiation feeding with CLOF were markedly different than with 
DHEA or PFOA, i.e., a reduction in tumor incidence (p< 0.08) and multiplicity (p< 0.004) 
was observed (Fig. 2.1). These results might be attributed to depressed growth as the 
clofibrate-fed trout were much smaller than controls (Table 2.1). However, DHEA also 
markedly inhibited growth, whereas, PFOA had little effect and both of these compounds 
yielded higher tumor incidences. Therefore, no consistent relationship between growth and 
sensitivity to tumor enhancement is obvious in this study. 
The ability of these peroxisome proliferators to act as complete carcinogens was 
also examined by feeding the same diets to sham-initiated trout. Consumption of dietary 
DHEA at 0.18% for 30 weeks resulted in 20% of the trout developing liver tumors (Table 
2.1). No tumors were seen in non-initiated trout fed the control, CLOF or PFOA diets. 
Historically the spontaneous liver tumor incidence in trout of this age is about 0.1%. 
Histological examination of AFB i- initiated trout confirmed previous findings from 
our laboratory (35) that mixed carcinomas are the predominant tumor type in AFB1- initiated 
trout. Neither PFOA or DHEA appeared to alter the tumor types which occurred in AFB1­
initiated trout, however post-initiation feeding of CLOF produced a unique shift in tumor 44 
type to solely cholangiocellular carcinomas and cholangiomas (Table 2.2). The alterations 
in tumor type by CLOF, however, may be the result of the toxicity and high mortality 
which occured in these treatment groups. 
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Figure 2.1.  Tumor incidence and multiplicity in trout initiated with AFB IL followed by 
30 weeks dietary exposure to peroxisome proliferators (Experiment 1).  The values 
represent one tank/treatment with each tank containing between 68-100 individuals. The 
trout were initiated as fry by immersion in a solution of 0.01 ppm for 30 min. All groups 
were fed control diet for the next 3 months, followed by experimental diets for 30 weeks 
prior to study termination. *Indicates a significant difference in tumor incidence compared 
to controls at p<0.08. **Indicates a significant difference in tumor incidence compared to 
controls at p<0.0001. #Indicates a significant difference in tumor multiplicity at p<0.004 
compared to controls.  ##Indicates a significant difference in tumor multiplicity at 
p<0.0001. 45 
Table 2.1.  The effect of dietary peroxisome proliferators on body weight, mortality, 
and tumor incidence (Experiment 1). 
Treatment  Body Wt.a (g)  Mortalityb (%)  Tumor 
Initiation/Promotion  Incidence (%) 
None/OTD  107 ± 29  15  0/85 (0) 
None/0.18% CLOF  44* ± 18  40  0/60 (0) 
None/0.44% CLOF  23* ± 8  29  0/71 (0) 
None/0.18% DHEA  28* ± 10  5  19/95 (20) 
None/0.02% PFOA  75 ± 18  0  0/100 (0) 
None/0.18% PFOA  78 ± 28  25  0/75 (0) 
AFB i/OTD  92 ± 25  0  36/100 (36) 
AFB 1 /0.18% CLOF  33* ± 12  0  32/100 (32) 
AFB1/0.44% CLOF  23* ± 8  32  14/68 (21) 
AFB1/0.18% DHEA  31* ± 9  10  90/90 (100) 
AFB1/0.02% PFOA  76 ± 17  0  34/100 (34) 
AFB 1 /0.18% PFOA  75 ± 22  10  64/90 (71) 
a Values are average body weights ± S.D. at the conclusion of the tumor study. 
b These values are based on the number of animals remaining at the conclusion of the 
tumor study. 
* indicates significant difference in body weight compared to control (p < 0.05). 
Table 2.2.  The effect of dietary peroxisome proliferators on tumor types in AFB1­
initiated trout (Experiment 1). 
Treatment  Classification of Tumors (%)-4­
Initiation/Promotion  MC  HCC  CCC  MA  HCA  Ch  BF 
None/None  0  0  0  0  0  0  0 
None/0.18% CLOF  0  0  0  0  0  0  0 
None/0.44% CLOF  0  0  0  0  0  0  0 
None/0.18% DHEA  67  25  0  4  4  0  0 
None/0.02% PFOA  0  0  0  0  0  0  0 
None/0.18% PFOA  0  0  0  0  0  0  0 
AFB 1/None  54  10  10  5  3  5  12 
AFB 1 /0.18% CLOF  15  0  74  0  2  7  2 
AFB 1/0.44% CLOF  0  0  81  0  0  19  0 
AFB1/0.18% DHEA  72  25  <1  0  1  1  <1 
AFB i/0.02% PFOA  50  11  16  5  0  14  5 
AFB1/0.18% PFOA  37  46  1  2  8  1  5 
aAbbreviations: MC = mixed carcinoma, HCC = hepatocellular carcinoma, CCC = 
cholangiocellular carcinoma, MA = mixed adenoma, HCA = hepatocellular adenoma, Ch 
= cholangioma, BF = basophilic foci 46 
The analysis of liver palmitoyl CoA oxidation in trout fed peroxisome proliferators 
for 27 weeks, shows no induction of peroxisomal enzyme activities by CLOF, DHEA or 
PFOA (Fig. 2.2).  In fact, peroxisomal B-oxidation activity was significantly reduced by 
the highest dose level of each compound. These results indicate that trout are relatively 
insensitive to peroxisome proliferation even at doses which cause considerable toxicity. 
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Figure 2.2.  Peroxisomal B-oxidation activity after 27 weeks of dietary peroxisome 
proliferators (Experiment 1).  Six trout were sampled from the noninitiated treatment 
groups, livers removed and assayed for palmitoyl CoA oxidation activity as described in 
Materials and Methods. Values represent means of three measurements per treatment plus 
SEM. A * indicates significantly different from controls (p < 0.05). 
Experiment 2 
The dose levels used in the first experiment clearly exceeded the maximum tolerated 
doses. Therefore, a followup tumor study was conducted to examine a lower range of 
doses of CLOF, PFOA, and DHEA. The DHEA portion of this study is presented 47 
separately in chapter 3. The CLOF and PFOA doses used in the second experiment were 
well tolerated as there was little mortality, and body weights were not significantly different 
from controls except in the AFB1- initiated, high PFOA treatment group (Table 2.3.). 
Table 2.3.  The effect of dietary peroxisome proliferators on body weight, mortality, 
and liver somatic index (Experiment 2). 
Treatment  Body Wt.a  Mortalityb  Liver Somatic 
Initiation/Promotion  (g)  (%)  Index c (%) 
None/OTD  81 ± 29  1  0.68 ± 0.09 
None/111 ppm CLOF  73 ± 35  0  0.68 ± 0.11 
None/222 ppm CLOF  73 ± 36  0  0.71 ± 0.12 
None/444 ppm CLOF  73 ± 32  0  0.71 ± 0.09 
None/222 ppm PFOA  76 ± 31  0  0.67 ± 0.10 
None/444 ppm PFOA  84 ± 30  0  0.64 ± 0.08 
None/888 ppm PFOA  75 ± 33  0  0.88 ± 0.66 
AFB i/OTD  85 ± 36  0  0.68 ± 0.09 
AFB1/111 ppm CLOF  88 ± 36  0  0.70 ± 0.12 
AFB1/222 ppm CLOF  74 ± 30  0  0.69 ± 0.09 
AFB1/444 ppm CLOF  77 ± 34  0  0.70 ± 0.15 
AFB 1/222 ppm PFOA  89 ± 32  0  0.61* ± 0.06 
AFB1/444 ppm PFOA  77 ± 30  0  0.67 ± 0.09 
AFB i/888 ppm PFOA  76 ± 32  1  0.76* ± 0.12 
AFB1/1108 ppm PFOA  71* ± 30  0  0.85* ± 0.14 
aValues are average body weights ± S.D. at the conclusion of the tumor study. 
bThese values are based on the number of animals remaining at the conclusion of the tumor 
study. 
cValues are average liver somatic indexes (% of body weight made up by liver) ± S.D. at 
the conclusion of the tumor study. 
* indicates significantly different from the appropriate controls (p < 0.05). 
CLOF treatment increased peroxisomal palmitoyl CoA oxidation in a dose-
dependent manner with the top two treatment groups having significantly higher activity 
than in controls (fig. 2.3). This enzyme activity was 1.8-fold higher in trout fed 444 ppm 
CLOF for 29 weeks than in animals fed control diet. There were no significant alterations 
in peroxisomal B-oxidation in PFOA-treated trout. Catalase activity was not increased by 
either CLOF or PFOA (fig. 2.4). 48 
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Figure 2.3.  Peroxisomal 13-oxidation activity after 29 weeks of dietary peroxisome 
proliferators (Experiment 2).  Twelve trout were sampled from the noninitiated 
experimental diet groups, livers removed and assayed for palmitoyl CoA oxidation activity 
as described in Materials and Methods. Values represent means of 12 measurements per 
treatment plus SEM. A * indicates significantly different from controls (p < 0.05). 
As observed in the previous study, neither CLOF or PFOA produced tumors in 
sham-initiated trout (Table 2.4). The results in the AFB1-initiated trout were considerably 
different than the preliminary study, however. Treatment with 111-444 ppm CLOF did not 
significantly alter tumor incidence. No protection towards AFB 1- initiated 
hepatocarcinogenesis was observed at these doses of CLOF. The tumor types observed in 
CLOF-treated trout were predominantly mixed carcinomas rather than the cholangiocellular 
tumors observed in experiment 1. In contrast to the tumor enhancement which occurred 
when initiated trout were fed 1800 ppm PFOA in the preliminary experiment, doses of 444­49 
888 ppm PFOA provided significant protection towards AFBI carcinogenesis (p < 0.05). 
At a dose of 1108 ppm, however, tumor incidence was slightly increased compared to 
initiated controls (Table 2.4). 
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Figure 2.4.  Catalase activity in peroxisome proliferator-fed trout (Experiment 2).
Twelve trout were sampled from each of the noninitiated groups after 29 weeks on 
experimental diets, livers removed and assayed for catalase activity as described in 
Materials and Methods. Values represent means of 12 measurements per treatment plus 
SEM. A * indicates significantly different from controls (p < 0.05). 50 
Table 2.4.  Liver tumor incidence and histological classification in AFB1-initiated trout 
fed peroxisome proliferators for 30 weeks. 
Treatment  Tumor Incidence 
% of total tumors by tumor typea 
MC  HCC  MA  HCA CCC  CA 
(%)b 
OTD  11/84 (13.1)  61  28  0  11  0  0 
111 ppm CLOF  15/78 (19.2)  63  26  0  7  4  0 
222 ppm CLOF  12/91 (13.0)  60  27  0  13  0  0 
444 ppm CLOF 
222 ppm PFOA 
15/83 (18.1) 
10/75 (13.3) 
53 
30 
24 
10 
0 
30 
18 
30 
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0 
0 
0 
444 ppm PFOA  7/84 (8.3)*  29  14  0  57  0  0 
888 ppm PFOA  4/89 (4.5)*  80  20  0  0  0  0 
1108 ppm PFOA  19/85 (22.4)  48  33  7  7  0  3 
a Abbreviations: MC, mixed carcinoma; HCC, hepatocellular carcinoma; MA, mixed 
adenoma; HCA, hepatocellular adenoma; CCC, cholangiocellular carcinoma; CA, 
cholangiocellular adenoma. 
b * indicates significantly different tumor incidence from initiated trout fed OTD (p < 0.05). 51 
DISCUSSION 
The compounds examined in this study are representative of a class known as 
peroxisome proliferators. These agents induce the levels of a number of peroxisomal and 
microsomal enzymes involved in the B- and (0-oxidation of fatty acids, respectively (2, 5, 
36-38). Prolonged exposure to peroxisome proliferators can be carcinogenic in rodents, 
however the mechanism of peroxisome proliferator hepatocarcingenesis is still unknown. 
A marked species difference has been observed with respect to the peroxisome 
proliferators, with primates described as resistant, compared to rodents (6, 7). As a result, 
the risk that these compounds represent to humans is uncertain. In this study, we have 
examined the carcinogenic properties of three peroxisome proliferators in rainbow trout, a 
species which, like humans, is relatively resistant to peroxisome proliferation. 
Dietary exposure for seven months to the highest dose (0.18%) of PFOA 
significantly enhanced the yield and multiplicity of tumors in AFB1- initiated trout. DHEA 
was even more potent, as 0.18% in the diet raised the incidence to 100%, there were 
markedly more tumors/liver, and tumors were significantly larger. Somewhat surprisingly, 
DHEA was carcinogenic by itself, as feeding 0.18% in the diet for seven months produced 
a 20% incidence of hepatocarcinogenesis. This adrenal steroid has been shown to be 
chemopreventive toward a number of disease states, including cancer (24, 39, 40), 
however, prolonged exposure  in  rats  has been demonstrated to produce 
hepatocarcinogenesis with a phenotype similar to ciprofibrate-induced tumors (27, 28). 
CLOF treatments failed to enhance tumorigenesis in control or AFB1- initiated trout. 
In fact, the higher dose (0.44%) significantly reduced the incidence and multiplicity of 
AFB 1- initiated tumors.  Furthermore, a shift in tumor type was observed, from 
predominantly mixed carcinomas to cholangiocellular carcinomas and cholangiomas. 
These effects are probably due to the toxicity of this dose of CLOF, as lower, less toxic 
doses of CLOF had no effect on tumor incidence or type. PFOA had mixed dose­52 
dependent effects on AFB 1- initiated carcinogenesis as well. Although high doses enhanced 
carcinogenesis, lower doses provided protection. The protective effects of PFOA do not 
appear to be due to growth inhibition, because these doses of PFOA did not cause reduced 
weight gain. The potent peroxisome proliferator WY 14,643 has also been shown to 
inhibit AFB1-initiated hepatocarcingenesis in rainbow trout (41). 
This study confirms previous reports that trout are weak responders to peroxisome 
proliferators (13, 42). The cacinogenicity of DHEA, and tumor modulating effects of 
DHEA, PFOA, and CLOF do not appear to require peroxisome proliferation. In fact, the 
treatment which produced the greatest increase in peroxisomal B-oxidation had no 
significant effect on tumor incidence. Liver somatic indexes were increased, however, in 
treatments which enhanced carcinogenesis. Trout may be useful models for further study 
of this class of compounds, because they resemble primates in being relatively resistant to 
peroxisomal proliferation, have a very low liver tumor background, are sensitive to 
chemically-initiated carcinogenesis and are promoted by agents which induce oxidative 
stress (43, 44). We have shown that two of the three compounds tested could initiate or 
enhance hepatocarcinogenesis in trout by mechanisms which are independent of 
peroxisome proliferation. 53 
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ABSTRACT
 
Dehydroepiandrosterone (DHEA), fed for 30 weeks to rainbow trout after initiation 
with the hepatocarcinogen aflatoxin B1 (AFB1), produced a dose-dependent enhancement 
of carcinogenesis as measured by increased tumor incidence, multiplicity and size. 
Significant enhancement was observed at 222 ppm, which corresponds to a daily dosage 
one-half that previously administered to humans in clinical trials. DHEA was also capable 
of acting as a complete carcinogen in this model, producing liver tumors at doses as low as 
222-444 ppm. Tumors isolated from trout treated with DHEA alone contained mutations in 
Ki-ras, primarily 12(1)G-4A transitions, providing the first evidence that DHEA could be a 
genotoxic carcinogen. The carcinogenicity of DHEA in trout is independent of peroxisome 
proliferation, as measurements of peroxisomal B-oxidation and catalase activity support 
previous observations that trout, like humans, are weak responders to peroxisome 
proliferators. 59 
INTRODUCTION 
Dehydroepiandrosterone (DHEA), and its sulfate (DHEA-S), produced by the 
adrenal gland, are the major circulating steroids in human plasma (reviewed in 1). The 
physiological function of DHEA, other than as a precursor for sex steroids in both males 
and females (2), is unknown. Human DHEA-S levels peak at about 25 years of age and 
subsequently decline with age (3) to about 10-20% of maximum. 
DHEA has been intensively studied owing to its wide range of chemopreventive 
properties in animal models toward a number of diseases including atherosclerosis, 
diabetes, obesity, lupus, and cancer (1, 4-6). DHEA is also being actively studied with 
respect to its anti-aging properties (5). In animal models DHEA has proven to be 
chemopreventive against spontaneous, viral, and chemically-induced tumors (4, 5). 
The clinical usefulness of DHEA as a chemopreventive agent is compromised by 
studies showing it to be a peroxisome proliferator and hepatocarcinogen in rodents (7-10). 
Long-term feeding of DHEA at 0.45% to male Fischer-344 (F-344) rats produces 
hepatocellular carcinomas (11). DHEA-initiated tumors in rats are phenotypically similar to 
those initiated by other peroxisome proliferators (11-13). The mechanism of peroxisome 
proliferator-induced hepatocarcinogenesis is still unclear, however and may not be the 
direct result of peroxisome proliferation. Trout, like humans are relatively insensitive to 
peroxisome proliferators (14, 15) and thus provide a useful alternative animal model to 
study these agents independent of peroxisome proliferation. 
Using this model, we now report dietary DHEA to be a complete carcinogen as well 
as a potent enhancer of aflatoxin Bi (AFB1)-initiated hepatocarcinogenesis in the absence 
of peroxisome proliferation. In addition, evidence is presented for the first time that DHEA 
may be genotoxic and capable of inducing Ki-ras mutations. These findings indicate that 
caution should be advised in the treatment of humans with DHEA until the mechanisms of 
DHEA carcinogenesis, and the implications for human cancer risk, are more thoroughly 
understood. 60 
MATERIALS AND METHODS
 
Materials 
DHEA (5-androsten-313-01-17-one), NADPH, and AFB I were purchased from 
Sigma Chem. Co. (St. Louis, MO). ReplithermTM DNA polymerase  was purchased from 
Epicenter Technologies (Madison, WI). Potassium cyanide was purchased from 
Mallinckrodt (Paris, Kentucky). All other reagents were purchased from Sigma. 
Animals and treatments 
Two tumor studies are described in this paper. Rainbow trout (Oncorhynchus 
mykiss) were hatched and reared at the Oregon State University Food Toxicology and 
Nutrition Laboratory in 12-14°C flowing well water. In the first experiment, fry (75 days 
post-spawning) were initiated by immersion in 10 ppb AFBI for 30 min. Sham-exposed 
fry were exposed to vehicle alone (0.01% ethanol) and served as non-initiated controls. 
Trout were fed Oregon Test Diet (OTD), a semi-purified casein-based diet (16), for an 
additional 16 weeks and then were divided into experimental groups and fed modified OTD 
diets (100 mg/kg vitamin E; rockfish oil substituted for salmon oil) containing 0, 55, 111, 
222, 444, or 888 ppm (w/w) DHEA for 30 weeks. DHEA was dissolved in the lipid 
component and mixed into the diet. Diets were prepared monthly and stored frozen. Once 
on experimental diets, trout were fed once daily, five times per week. Animals were fed 
only what could be consumed in 5 minutes and DHEA exposure by routes other than 
dietary is believed to be negligible. In the first experiment, each treatment group consisted 
of 70-100 trout, housed in a single 3 ft diameter (100 gal) continuous flow tank. In a 
separate experiment, the same five levels of DHEA were fed to noninitiated trout for 42 
weeks beginning 111 days after spawning. Duplicate tanks of 120 trout per dose level 
were used for this study for all doses except the noninitiated controls (single tank). Trout 
were killed by an overdose of MS-222 after 30 or 42 weeks on experimental diets and the 61 
body weights and liver weights measured. The liver was grossly examined for tumors and 
the incidence, multiplicity and size recorded. A portion of the tumors observed during 
necropsy were quick-frozen in liquid nitrogen and stored at -20°C for analysis of Ki-ras 
mutations. Livers were fixed in Bouin's solution for histological examination. After 48 hr 
tumors were hand sliced to verify previously seen tumors or detect internal, previously 
undetected, tumors. One slide per tumor-bearing liver, containing as many tumors as 
possible, was prepared and stained with hematoxylin and eosin for tumor identification. 
Classification of tumors was on the basis of criteria described previously (17). 
Enzyme assays 
The effects of dietary DHEA on peroxisomal enzyme activities in trout were 
examined by sampling twelve non-initiated individuals from each dietary dose of DHEA 
after 29 weeks. Animals were stunned and killed by decapitation. Livers were 
immediately removed from the animal and placed into ice cold homogenization buffer (60 
mM tris, 0.25 M sucrose buffer, pH 8.3). Three livers were pooled, homogenized, 
centrifuged at 600 g for 20 min (4°C) to pellet cell debris and nuclei, and the supernatant 
centrifuged at 12,000 g (4°C) for 30 min to obtain the mitochondrial/peroxisomal fraction. 
The 12,000 g pellet was resuspended and protein concentration determined by the method 
of Lowry et al., using bovine serum albumin as a standard (18). Cyanide-insensitive B-
oxidation of palmitoyl-CoA was followed spectrophotometrically via the reduction of 
NAD+ to NADPH at 340 nm (19, 20). Catalase activity was determined 
spectrophotometrically as the loss of absorption at 240 nm during the decomposition of 
hydrogen peroxide (21). 
Mutational analysis of Ki-ras 
Tumor tissue was digested with proteinase K and mutations in Ki-ras analyzed by 
3'-primer mismatch polymerase chain reaction (PCR) as described previously (22). 62 
Positive mutations were verified by a second primer mismatch analysis. In addition, some 
of the mutations were confirmed by direct sequencing. The initial PCR products from four 
tumors were sequenced on an automated cycle sequencer (Applied Biosystems, Inc., 
Foster City, CA). Predicted mutations were detected in three of the four samples. The 
ratio of mutant:normal ras alleles in the fourth tumor DNA may have been too low to permit 
detection by direct sequencing. 
Statistical analysis 
The effect of DHEA on tumor incidence was assessed by logistic regression. 
Fisher's exact test (two-tailed) was used to determine which treatment groups had 
significantly different tumor incidences than controls. DHEA enhancement of tumor size 
was determined by ANOVA of the log average size, followed by the Scheffe's test for 
pairwise comparisons. The nonparametric Kruskal-Wallis test was employed to compare 
the average number of tumors per animal in trout with tumors using chi-square 
approximation of p-values. In groups with differences, pairwise comparisons were made 
by the Wilcoxon Rank Sum test. Body and liver weight data were log transformed and 
analyzed by ANOVA followed by the Scheffe's test for pairwise comparisons. All 
statistical analysis was conducted using the Statistical Analysis System (SAS Institute, Inc. 
Cary, NC) version 6.04. 63 
RESULTS AND DISCUSSION 
Dietary DHEA produced a dose-dependent decrease in body weight, (p<0.0001). 
AFB1- initiated trout fed 444 ppm and higher levels of DHEA for 30 weeks had 
significantly (p<0.05) lower body weights at the conclusion of the study than controls in 
the AFB1- initiated group (Table 3.1). Non-initiated trout fed 888 ppm DHEA for 30 
weeks (Table 3.1) or 55 ppm or higher for 42 weeks (not shown) also had significantly 
lower body weights than controls. Similar decreases in weight gain have been observed in 
rodents in long-term DHEA feeding protocols (reviewed in 5). These observations have 
been the basis for the therapeutic use of DHEA in veterinary medicine as an anti-obesity 
Table 3.1. Trout body weights, liver weights, and relative liver weights after 30 weeks of 
dietary DHEA.a,b 
Treatment  Body Wt.b  Liver Wt.  Liver Somatic 
Initiation/DHEA  (g)  (g)  Index (%) 
Sham/0 ppm (n=77)  81c + 3  0.55c ± 0.02  0.68c ± 0.01 
Sham/55 ppm (n=78)  81c + 4  0.62c,d ± 0.03  0.76c,d ± 0.01
Sham/111 ppm (n=80)  76c,d + 3  0.62c,d ± 0.03  0.80d ± 0.01 
Sham/222 ppm (n=85)  70c4 + 4  0.64c4 ± 0.03  0.92e,f ± 0.01
Sham/444 ppm (n=86)  65c,d,e ± 3  0.72c,d ± 0.03  1.11g,h ± 0.01
Sham/888 ppm (n=88)  40f + 2  0.54c ± 0.03  1.351 ± 0.04 
AFB1/0 ppm (n=84)  85c ± 4  0.57c ± 0.03  0.68c ± 0.01 
73c,d + 3 AFB1/55 ppm (n=84)  0.62c4 ± 0.02  0.85d,e,f ± 0.02 
AFB 1 /1 11 ppm (n=76)  81c + 3  0.66c4 ± 0.03  0.81d,e,f ± 0.01 
AFB1/222 ppm(n=88)  66c,d,e ± 3  0.63c ± 0.03  0.96f,g ± 0.02
AFB1/444 ppm (n=100)  6001,e + 2  0.76c4 ± 0.04  1.2711,i ± 0.06 
AFB1/888 ppm (n=70)  52e,f + 3  1.12d ± 0.16  2.11J±0.21 2.11J
aValues are average body weight, liver weight, or liver somatic index at the conclusion of 
the study ± SE. 
bNumbers bearing the same superscripts are not significantly different from one another
(p<0.05) (within the same column). 64 
agent (23) and investigations into the potential for DHEA use in the treatment of human 
obesity (24). No effect of AFBI treatment on body weight was observed. 
DHEA produces hepatomegaly in rodents (8, 25-27) and we present evidence here 
for liver enlargement in a non-mammalian model which is much less responsive to 
peroxisome proliferation (14, 15). Liver somatic indices were elevated by dietary DHEA 
(Table 1) in a dose-dependent manner. Non-initiated and AFB 1- initiated trout treated for 
30 weeks with diets  111 ppm and  55 ppm DHEA, respectively, had significantly 
higher relative liver weights (p<0.05) than controls (Table 3.1). Part of this increase is due 
to the decreased body weights, however, absolute liver weights were also higher in DHEA-
fed trout. The markedly higher somatic indices in the AFB1- initiated groups fed the two 
highest DHEA diets is largely due to enhanced tumor tissue mass. 
In rodents, the DHEA-dependent enhanced liver somatic index is accompanied by 
marked increases in peroxisome size, number and enzymatic activity (7, 28). In trout, the 
hepatomegaly does not appear to be due to peroxisomal changes. Instead, electron 
microscopy reveals enlarged hepatocytes packed with rough endoplasmic reticulum. In 
addition, there is dramatic proliferation of biliary preductule cells (29). These hepatic 
changes are similar to those observed in mature female rainbow trout during the period of 
vitellogenesis (30) and probably are the result of DHEA conversion into androgens and 
estrogens rather than its peroxisome proliferating effects. 
DHEA administered by diet to AFB1-initiated trout enhanced tumor incidence in a 
dose-dependent manner (p=0.0001) from 13% (11/84 trout) in control diets to 97% (68/70 
trout) at 888 ppm DHEA (Fig. 1). The number of tumors per tumor-bearing animal was 
also significantly (p<0.0001) enhanced (Fig. 3.1).  Initiated trout fed control diet had an 
average of 1.4 ± 0.2 tumors per tumor-bearing animal. DHEA, fed at 222, 444 and 888 
ppm DHEA increased this value to 1.9 ± 0.2 (p<0.10), 3.9 ± 0.3 (p<0.0005) and 6.1 
0.4 (p<0.0001), respectively.  The size of tumors was also significantly (p<0.0001) 
enhanced by dietary DHEA in a dose-dependent manner. The average tumor diameter was 65 
1.3 ± 0.1 mm in initiated trout fed control diet. The two highest levels of DHEA (444 and 
888 ppm) increased the average tumor size two-(2.8 ± 0.2 mm) and three-(3.9 ± 0.3 mm) 
fold, respectively. 
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Figure 3.1. Liver tumor incidence and multiplicity in AFB I -initiated trout fed 0, 55, 111, 
222, 444 or 888 ppm DHEA. Each treatment group consisted of a single tank containing 
between 70 and 100 animals. A * indicates a significantly (p < 0.05) higher tumor 
incidence than controls. A # indicates significantly higher tumor multiplicity than controls. 
Dietary DHEA exposure was therefore, a highly effective post-initiation enhancer of 
AFB1-initiated hepatocarcinogenesis in trout. Tumor incidence, multiplicity and size were 
all significantly increased in a dose-dependent manner. The enhancement in incidence was 
significant at dietary doses as low as 222 ppm. Enhancement of carcingenesis by DHEA 
has previously been observed in rodent studies, however much higher doses were utilized. 66 
For example, feeding male Lewis rats initiated with azaserine, 6000 ppm DHEA for 4 
months post-initiation, produced a 75% increase in the incidence of pancreatic preneoplastic 
lesions (31). SWXJ-9 Mice fed 4000 ppm DHEA for 50 days exhibited a 6-fold increase in 
spontaneous ovarian granulosa cell tumors (32). 
In addition to enhancing AFB 1- initiated hepatocarcinogenesis, DHEA was a 
complete carcinogen producing a dose-dependent increase in tumor incidence (p<0.0001) 
in non-initiated trout fed DHEA for 30 or 42 weeks (Fig. 3.2). Sixty-eight percent of 
animals fed the highest dose of DHEA for 42 weeks developed tumors while no tumors 
were detected in the non-initiated controls. There were also significantly more tumors per 
liver in trout fed 444 or 888 ppm DHEA for 42 weeks, or 888 ppm DHEA for 30 weeks 
compared to the next highest treatment (not shown). Trout appear to be much more 
susceptible than rats to DHEA as a complete carcinogen. For example, Rao et al., reported 
that feeding 4500 ppm DHEA to male F-344 rats for 84 weeks was hepatocarcinogenic in 
15/16 animals (11). However, Moore et al., found that feeding F-344 rats diets containing 
6000 ppm DHEA for 9 months did not produce liver or lung tumors in either sex (33). 
Classification of liver tumors was based on a subsample of the total tumors 
evaluated, i.e., those present in the one slide prepared from each tumor bearing liver. For 
livers with one to only a few tumors, we would have seen all or most of the tumors, for 
heavily tumored livers, we would have seen only a part of the total. The same array of 
hepato- and cholangiocellular tumors were seen as was previously described (17), 
however, the relative percentages of some tumor types differed from what has been 
reported with other carcinogen-initiation protocols. In previous studies using AFB1 (34), 
N-nitrosodiethylamine (35), and 7,12-dimethylbenz[a]anthracene (22), the mixed 
hepatocholangiocellular carcinoma (MC) was the predominant tumor type (about 60% of all 
tumors), with hepatocellular carcinomas (HCC) second in number (20-30%), and all other 
types [mixed adenomas (MA), hepatocellular adenomas (HCA), cholangiocellular 
carcinomas (CCC), and cholangiomas (Ch) making up the final 10-20%. In the current 67 
study, AFB I alone produced a similar spectrum of tumors (Table 3.2), but DHEA 
promotion resulted in a shift from MC (down to the 30% range) to HCA (up to the 20-30% 
range), while HCC remained about the same. DHEA initiation alone, however, produced 
the more normal pattern of MC>HCC>HCA. 
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Figure 3.2. Liver tumor incidence and multiplicity in sham and non-initiated trout fed 0, 
55, 111, 222, 444, or 888 ppm DHEA for 30 or 42 weeks. For the 30 week experiment, 
each treatment group consisted of a single tank containing between 77 and 88 animals. The 
42 week study utilized duplicate tanks of 100 trout per treatment. Liver tumors in the 42 
week experiment have not yet been confirmed by histological examination, however we 
have found that tumor incidence based on gross examination is an excellent approximation 
of final tumor incidence. A * indicates a significantly (p < 0.05) higher tumor incidence 
than controls. 
The combined effects of AFB1 and DHEA are clearly more than the additive effects 
of AFBI and DHEA acting as initiators. Thus, it would seem reasonable that DHEA is 
promoting clones of cells that were initiated by AFBi but would not have developed into 68 
recognizable tumors with that treatment alone. We believe that the benign HCA is a 
progressive step towards the malignant HCC, and in most cases not a terminal lesion. 
Thus, the increased number of HCA observed with DHEA promotion may represent a late 
stage promotion of AFB 1- initiated lesions that have not had sufficient time to develop 
malignancy. 
Table 3.2. Histological classification of liver tumors in trout fed DHEA for 30 weeks. 
% of total tumors by tumor typea 
Treatment  MC  HCC  MA  HCA  CCC  Ch 
Initiation/DHEA 
Shaxn/O ppm  0 0 0  0 0 0 
Sham/55 ppm  0  0  0  0  0 0 
Sham/111 ppm  0  0  0  0  0  0 
Sham/222 ppm  0  0  0  0  0  0 
Sham/444 ppm  70  20  0  0  0  10 
Sham/888 ppm  53  36  3  9  0  0 
AFB1/0 ppm  61  28  0  11  0  0 
AFB 1/55 ppm  50  32  0  18  0  0 
AFB1/111 ppm  36  43  0  18  0  4 
AFB1/222 ppm  39  40  0  22  0  0 
AFB1/444 ppm  30  36  2  32  0  1 
AFB 1/888 ppm  39  31  5  25  0.3  0 
aAbbreviations: MC, mixed carcinoma; HCC, hepatocellular carcinoma; MA, mixed 
adenoma; HCA, hepatocellular adenoma; CCC, cholangiocellular carcinoma; Ch, 
cholangiomas. 
The potential for DHEA to function as a peroxisome proliferator in trout was 
determined by assays of palmitoyl CoA 13-oxidation and catalase. Dietary DHEA did not 
significantly (p<0.05) alter palmitoyl CoA oxidation at any dose (Fig 3.3). The group fed 
888 ppm DHEA exhibited a mean increase of 40% but this was not significant at p<0.05. 69 
Catalase activity was not elevated, and in fact was significantly (p<0.0005) decreased by 
dietary DHEA in a dose-dependent manner (Fig. 3.4). The highest dose of DHEA 
produced a 2.5-fold decrease in catalase activity. 
A clear distinction between rat and trout with respect to DHEA as a 
hepatocarcinogen, exists not only with respect to potency, but also with the observation 
that the latter species is relatively insensitive to the peroxisome proliferating properties of 
DHEA. Long-term feeding of DHEA to trout does not enhance B-oxidation of palmitoyl 
CoA and significantly decreases catalase activity at the higher doses. 
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Figure 3.3.  Peroxisomal palmitoyl CoA B-oxidation in non-initiated trout fed diets 
containing 0, 55, 111, 222, 444 or 888 ppm DHEA for 6 months. Twelve trout from each 
DHEA dose were removed 1 week prior to the conclusion of the study. Peroxisomal B-
oxidation was measured as described in Materials and Methods. The bars represent the 
mean ± S.E. of 4 pools of 3 livers. A * indicates significantly (p < 0.05) different from 
controls. 70 
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Figure 3.4. Peroxisomal catalase activity in non-initiated trout fed diets containing 0, 55, 
111, 222, 444 or 888 ppm DHEA for 6 months. Twelve trout from each DHEA dose were 
removed 1 week prior to the conclusion of the study. Peroxisomal B-oxidation and catalase 
activities were measured as described in Materials and Methods. The bars represent the 
mean ± S.E. of 4 pools of 3 livers. A * indicates significantly (p < 0.05) different from 
controls. 
Ki-ras mutations in a significant percentage of DHEA-induced tumors support its 
action as a complete carcinogen in trout. The presence of mutated Ki-ras oncogenes in 
DNA isolated from hepatic tumors of trout was examined in two seperate experiments 
using primer mismatch PCR. Tumor DNA from a preliminary experiment in which trout 
were fed 1800 ppm DHEA for six months was analyzed. Fifty percent (3/6) of the tumors 
carried activated Ki-ras and both 12(1) G-4A transitions (1/6) and 13(2) G-1­
transversions (2/6) were observed (Table 3.3). Tumor DNA from trout initiated with 
AFB I exhibited an incidence of 84 and 86% activated Ki-ras in groups fed control diet or 
1800 ppm DHEA, respectively. In addition, as previously observed in AFB i- initiated 
trout, the mutations were predominantly 12(2) G -T transversions (Val12 p21) both with 71 
and without DHEA. In the present study, approximately 1/3 of the tumors isolated from 
sham-initiated trout fed 888 ppm DHEA for 30 weeks contained mutated Ki-ras and the 
mutation was exclusively a GA transition at the first G of codon 12 (Table 3.3). This 
mutation would result in expression of a Arg12 p21. 
Table 3.3. Ki-ras mutations in DNA from trout liver tumors.a 
Treatment  Ki-ras mutations 
Initiation/DHEA  %Tumorb  12(1)GA  12(2)G .A  12(2)G -*T  13(2)G -T 
Preliminary Studyc 
AFB1/0 ppm  36  2/32  ndd  22/32  3/32 
AFB1/1800 ppm  100  1/29  nd  17/29  7/29 
Sham/1800 ppm  20  1/6  nd  0/6  2/6 
This Studye 
Sham/888 ppm  41  8/25  0/25  0/25  0/25 
aMutations were identified by 3' primer mismatch PCR as described previously (22). 
bThe percentage of animals with tumors (number of individuals sampled per group was 87­
100).
 
cTrout fry were initiated by 10 ppb AFBi for 30 min and fed either control diet or 1800
 
ppm DHEA for 28 weeks.
 
dnd signifies not determined.
 
eTrout fry were sham initiated and fed OTD containing 888 ppm DHEA for 30 weeks as
 
described in Materials and Methods. 
The trout Ki-ras oncogene is highly homologous to human Ki-ras (36) and is 
mutated in approximately 80% of hepatic tumors induced by AFB1, 7,12­
dimethylbenz[a]anthracene (DMBA) or 1-methyl -3-nitro-l-nitrosoguanidine (MNNG) (22, 
37, 38). However, the mutational spectrum differs for each of these initiators. AFB 
initiation induces primarily codon 12(2) G -T transversions, with smaller amounts of 13(2) 72 
G--a transversions and 12(1) G-->A transitions (38). Initiation with DMBA, on the other 
hand, yielded equal amounts (4/11) of 12(1) G -A transitions and 12(2)Ga 
transversions, with a single observed 61(2) Aa transversion (22). Hepatocarcinogenesis 
induced by MNNG produced almost entirely G-->A transitions in both codon 12 and 13 
(37). Our initial screening of 6 tumors from DHEA-fed trout indicated that 3 carried 
mutated Ki-ras. One mutation was a 12(1) GA transition and the other 2 were 13(2) 
Ga transversions. In a subsequent experiment, 8/25 tumors were positive for mutated 
Ki-ras, and all were 12(1) G -A transitions. The observation that we have yet to detect a 
Ki-ras mutation in the rare spontaneous liver tumors (0.1%), suggests that activated Ki-ras 
is important in the etiology of DHEA hepatocarcinogenesis in trout, as it appears to be with 
known genotoxic carcinogens such as AFB1, DMBA and MNNG. These results can be 
contrasted with K- and H-ras mutations from ciprofibrate-induced mouse liver tumors. In 
this tumor model the frequency of mutated ras in tumors from ciprofibrate-treated animals 
is lower than found in spontaneous tumors (39). We believe this to be the first report of 
oncogene activation by DHEA or, in fact, the first report of any genotoxicity associated 
with this compound. More extensive studies as spontaneous trout liver tumors become 
available will be needed to substantiate this finding. 
Human clinical trials have employed dosages of DHEA as high as 21-27 mg/kg 
daily for 28 days or a total dose of 600-750 mg/kg (40, 41). In this study, we have found 
that daily doses (trout were fed at 5.4% of their body weight 5 days per week) of 12 mg/kg 
for 30 weeks or a total dose of 1800 mg/kg significantly enhanced AFBi-initiated 
hepatocarcinogenesis in trout. DHEA was effective as a complete carcinogen at 12 
mg/kg/day for 30 weeks, or 6 mg/kg/day for 43 weeks. In the absence of evidence that the 
mechanism of DHEA-dependent carcinogenesis in trout is not applicable in humans, it 
would seem prudent to reconsider clinical trials involving supra pharmacological doses of 
DHEA administered over prolonged periods. 73 
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ABSTRACT
 
Dehydroepiandrosterone (DHEA) is an adrenal steroid which is being studied as a 
possible therapeutic agent for a wide variety of human diseases including cancer, diabetes, 
lupus, and AIDS. DHEA, however, is also a peroxisome proliferator and 
hepatocarcinogen in rats. Rainbow trout are relatively insensitive to the peroxisome 
proliferating effects of DHEA but are highly sensitive to its carcinogenicity. It is possible 
that the hepatocarcinogenicity of DHEA is caused by a different mechanism than that 
causing peroxisome proliferation. This study was designed to examine the time course of 
the histological and biochemical changes associated with administration of DHEA to trout. 
Rainbow trout (Oncorhynchus mykiss) were fed 0.18% DHEA and sampled after 0, 1, 2, 
4, 7, or 14 days of treatment. Significant increases in the liver wt. to body wt. ratio 
occurred by the fourth day of treatment. The increase in liver size appears to be due to a 
combination of hypertrophy of hepatocytes and proliferation of biliary preductule cells. 
Peroxisomal B-oxidation was significantly increased on the second day of treatment, but 
decreased on subsequent days. Catalase activity was reduced on days 7 through 14. 
Serum albumin, cholesterol, and direct bilirubin levels increased over the course of the 
study. The histological and biochemical changes associated with short-term administration 
of DHEA may be useful in elucidating the carcinogenic mechanism(s) of this compound. 79 
INTRODUCTION
 
The adrenal steroid dehydroepiandrosterone (DHEA) has been reported to have 
chemoprotective effects in a variety of rodent carcinogenesis models (1). DHEA, however, 
also causes hepatomegaly, proliferation of peroxisomes, and increases in peroxisomal B-
oxidation, characteristics of a group of nongenotoxic rodent carcinogens known as 
peroxisome proliferators (PPs) (2-5). Recently DHEA was shown to produce 
hepatocellular carcinomas in rats, possibly through peroxisome proliferation (6). 
Rainbow trout may prove to be an appropriate model for studying the mechanisms 
of PP carcinogenicity because their response to these compounds appears to be similar to 
that of primates. Rainbow trout treated for three weeks with the hypolipidemic drug 
ciprofibrate had significantly increased peroxisomal 13-oxidation and peroxisomal volume 
density, although to a lesser extent than typically seen in rodents exposed to the same levels 
(7). Our laboratory showed that DHEA was a liver carcinogen and a strong enhancer of 
aflatoxin B1 hepatocarcinogenesis in the trout tumor model (8). These effects were not 
accompanied by increases in peroxisomal B-oxidation or co-hydroxylation of fatty acids. 
DHEA treatment did result in dramatic increases in liver weights and histological changes 
including hypertrophy of hepatocytes and proliferation of presumptive bile preductule cells 
(9). This study was designed to examine the time course of the histological and 
biochemical changes associated with short-term administration of DHEA to trout. 80 
MATERIALS AND METHODS
 
Materials 
DHEA, palmitoyl-CoA, and NAD+ and other chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO). Western blotting reagents were purchased from 
Biorad (Hercules, CO). [1-14C] Lauric acid was obtained from American Radio labeled 
Chemicals, Inc (St. Louis, MO). Antibody to proliferating cell nuclear antigen (PCNA) 
was purchased from Paracelsian (Ithaca, NY). Vitellogenin antibody and standards were 
provided by Dr. David R. Idler (Memorial Univ. of Newfoundland, St. John's, 
Newfoundland, Canada). 
Experimental Animals 
Rainbow trout (Oncorhynchus mykiss) were spawned and raised in our laboratory. 
Six months after spawning, 500 juvenile trout (average wt 18 g) were fed Oregon test diet 
(OTD) (10) containing 0.18% (w/w) DHEA for up to 18 days. Animals were housed in a 
single 4 ft. tank with continuously flowing, 12° well water and a 12 hour light dark cycle 
and were fed 2% of their body weight once per day. Fish were sampled prior to beginning 
experimental diets and after 1, 2, 4, 7, and 14 days of treatment between 8 and 10  am. In 
addition, some trout were kept on experimental diets for 4 additional days (until day 18), 
then were sampled on day 21 for light and electron microscopy. On the day of sampling, 
trout were anesthetized with MS-222, weighed, blood was drawn from the caudal vein, 
and livers removed, weighed, and placed into the appropriate fixative or buffer. 
Clinical Chemistry 
Serum was obtained by centrifugation of pooled blood samples (6 pools of 10 fish 
each). Bilirubin, albumin, cholesterol, and glutamic-oxaloacetic transaminase (SGOT) 
were measured using a Ciba Corning 550 Express automated analyzer according to 81 
manufacturer's instructions. Serum DHEA and DHEA-sulfate were determined by 
radioimmunoassay (Wien Laboratories, Succasunna, NJ) and vitellogenin with an enzyme 
linked immunosorbent assay (11). 
Enzyme Assays 
Sixty fish were sampled at each time point. Pools of ten livers were homogenized 
(20% w/v) in 60 mM Tris, 0.25 M sucrose buffer (pH 8.3) and separated by differential 
centrifugation into nuclear (600 g.), mitochondrial (12,000 g.), and microsomal (105,000 
g.) fractions. The mitochondrial/peroxisomal fraction was used to measure peroxisomal B-
oxidation and catalase activity.  Cyanide insensitive B-oxidation was monitored by 
spectrophotometrically measuring the reduction of NAD+ to NADH in the presence of 
palmitoyl-CoA (12). Catalase activity was measured by monitoring the decomposition of 
hydrogen peroxide (13).  Protein was measured using the Bradford method (14). 
Microsomes were incubated with [1-14C] lauric acid, then hydroxylated products extracted 
with ethyl acetate and separated by HPLC (15).  Total P450 was measured by 
spectrophotometrically comparing the reduced versus the oxidized carbon monoxide 
difference spectrum (16). The protein concentration of the microsomal fractions was 
determined according to the method of Lowry et al., using bovine serum albumin as a 
standard (17). 
Protein Separation and Western Blotting 
Proteins were separated using polyacrylamide gel electrophoresis (10%) in the 
presence of sodium dodecyl sulfate (SDS-PAGE) (18) . They were blotted onto 
nitrocellulose (Buchler semi-dry blotter, Lenexa, KS); and blots probed with a mouse 
monoclonal antibody to rat PCNA followed by a horseradish peroxidase linked secondary 
antibody. PCNA was detected by chemiluminescence (Amersham Corp., Arlington 
Heights, IL). The blots were scanned on a flatbed scanner (HP Scan Jet IIcx) and relative 82 
densities of the bands analyzed with the public domain software NIH Image, version 1.54 
(written by Wayne Rasband at the National Institute of Health and available by anonymous 
ftp from zippy.nimh.nih.gov over the internet) on a Power Macintosh 7100. 
Light Microscopy 
Livers were fixed in Bouin's solution, processed to paraffin sections via 
conventional methods, and stained with hematoxylin and eosin (H&E). 
Transmission Electron Microscopy 
Livers from control and DHEA-treated fish were sampled at ten weeks and 
processed for electron microscopy. One mm thick slices were excised and immecliatly 
fixed by immersion in phosphate buffered 4% formaldehyde-1% glutaraldehyde fixative at 
4°C for two hours. Tissues were then post fixed in 1.0% 0s04 for one hour, dehydrated 
and embedded in epoxy resin. Ultrathin sections of 60 to 80 nm were cut and subsequently 
stained with uranyl acetate and bismuth subnitrate. Specimens were examined in a Zeiss 
EM 10/A transmission electron microscope at an accelerating voltage of 60 kV. 
Statistical Analysis 
Data were analyzed using one-way ANOVA (with and without log transformation) 
followed by the Fisher PLSD test. Data analysis was performed using StatView 512+ 
(Brainpower, Calabasas, CA) on a Macintosh computer. P-values of 0.05 or less were 
considered significant. 83 
RESULTS
 
Dietary administration of 0.18% DHEA caused increases in the percent of body 
weight made up by liver (Fig. 4.1). Relative liver weight increased in a linear manner and 
on day 14 was 90% higher than on day 0. The increase in the percent of body weight made 
up by livers was not due to decreased animal weights as DHEA-treated  trout continued to 
gain weight (average weight gain during the 14 days was 7.8 g) (Table 4.1). 
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Figure 4.1.  The effect of dietary DHEA  on percent liver weights (g liver/100 g body 
weight). * = significantly different from day 0 (p < 0.05). 
Dietary DHEA produced rapid increases in serum DHEA  from nondetectable levels 
in untreated animals to more than 90 mg/dl on the second day of treatment (Table 4.1). 
This is within the normal human range for DHEAS, however in trout, the steroid appears 
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to be present primarily as DHEA rather than the sulfated form. Serum DHEA  levels then 
declined to 6.3 mg/dl on the 14th day of dietary DHEA. This may represent increased 
metabolism of DHEA  or binding to serum proteins or lipids. Serum cholesterol was 
significantly elevated on the 4th, 7th, and 14th days of treatment. SGOT was elevated on 
days 1, 2, and 14 (Table 4.1). 
Table 4.1.  Body weights, and serum DHEA,  cholesterol, and SGOT in trout fed 
0.18% DHEA  for up to 14 days. 
Timea  Fish Wt.b,e  Serum  Serum  Serum 
(days)  (g)  DHEAb,d  Cholesterolb,e  SGOTb,e 
(gg/dL)  (mg/dL)  (mg/dL) 
0  18.21 ± 0.81  not detected  125 ± 1  290 ± 29 
1  17.98 ± 0.68  76.0f + 6.4  120 ± 3  489f ± 26 
2  19.40 ± 0.65  93.3f + 7.3  130 ± 5  458f + 29 
4  19.16 ± 0.63  53.0f + 3.5  216f ± 12  390 ± 26 
7  22.58f ± 0.79  39.7f± 10.4  181f ±11  345± 10 
14  26.08f ± 0.76  6.3 ± 3.5  221f + 6  473f + 28 
a  Number of days of treatment with 0.18% DHEA 
b Values are means ± SEM 
e  Number of animals (n) = 67 
d Values are means ± SEM of three measurements 
e  Values are means ± SEM of four measurements 
f  Significant differences from day 0 values were determined by one-way ANOVA 
followed by Fisher PLSD  on log transformed data. (p < 0.05) 
Peroxisomal and microsomal enzymes were measured to determine if DHEA causes 
peroxisome proliferation in trout as in rodents (Table 4.2). Palmitoyl CoA oxidation was 
increased by 2-fold on the fourth day of treatment. The induction was transient, however, 
and after 14 days of treatment activity was significantly lower than controls. Peroxisomal 
catalase activity was significantly decreased beginning on the fourth day of dietary  DHEA. 
Total microsomal P450 content was reduced at all time-points compared to controls. 85 
Hydroxylation of lauric acid was not significantly enhanced by DHEA treatment. No 
hydroxylation was observed at the co position. Recently Buhler et al. demonstrated that, 
although the 0)-1 hydroxylated product is the major metabolite of lauric acid produced by 
juvenile trout microsomes, hydroxylation at the co-2, 0)-3, co-4, 0)-5, and co-6 positions also 
occurs (19). The HPLC conditions used in this experiment did not separate 0)-1 from co-2 
through co-6. There were no differences in the overall hydroxylation of lauric acid 
throughout the 14 days of DHEA treatment, however, we cannot rule out the possibility 
that the ratio of co-1 to other hydroxylated products was changed. Overall, the enzyme 
data support the classification of trout as weak responders to peroxisome proliferators. 
Table 4.2.  Peroxisomal and microsomal enzymes in DHEA-treated trout. 
Timea  Palmitoyl CoA  Catalaseb  Lauric Acid  Total P450b 
(days)  Oxidationb,c  (Units/min/mg )  hydrox.b  (nmol/mg) 
(nmol/min/mg )  (nmol/co-1 /min/nmol 
P450) 
0  56.6 ± 6.4  622 ± 48  0.945 ± 0.411  0.42 ± 0.03 
1  52.5 ± 4.9  632 ± 47  0.856 ± 0.374  0.20C ± 0.02 
2  105.9C ± 8.3  432C ± 36  1.455 ± 0.560  0.30C ± 0.03 
4  45.5 ± 4.4  482 ± 30  2.654 ± 1.861  0.27C ± 0.03 
7  65.2 ± 5.4  340c ± 28  1.186 ± 0.169  0.31C ± 0.03 
14  17.1C ± 1.8  206C ± 7  1.271 ± 0.170  0.27C ± 0.02 
a Number of days of treatment with 0.18% DHEA 
b Values are means ± SEM of six measurements 
Significant differences from day 0 values were determined by one-way ANOVA 
followed by Fisher PLSD on log transformed data. (p < 0.05) 
In addition to being enlarged, livers of DHEA-treated fish were yellow and animals 
appeared jaundiced. Serum levels of bilirubin were elevated, primarily in the direct 
(conjugated) form (Figure 4.2). 86 
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Figure 4.2.  Serum bilirubin levels in trout fed 0.18% DHEA for up to 14 days. * = 
significantly different from day 0 (p < 0.05). 
Light Microscopy 
Livers of DHEA-treated trout were examined by light and electron microscopy. 
The first four days of treatment resulted in increased mitotic activity, decreased glycogen 
levels, nuclear swelling, and hepatocyte enlargement (Fig. 4.3-4.5). Proliferation of small 
biliary preductule cells within the hepatic tubules was observed on days seven through 
twenty-one, hepatocytes were swollen, and mitotic figures were common (Fig. 4.6-4.8). 
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Figure 4.3.  Control liver from a six-month old rainbow trout, demonstrating tubular 
architecture, abundant glycogen, and no mitotic figures. Bar, 50 mm; X 563. 88 
Figure 4.4.  Section of liver from a rainbow trout after receiving 0.18% dietary DHEA 
for one day. Some hepatocyte nuclei appear enlarged (arrowheads), glycogen vacuolation 
is slightly reduced and a mitotic figure (arrow) is present. Bar, 50 mm; X 563. 89 
Figure 4.5.  Trout liver section after four days on 0.18% dietary DHEA. Glycogen 
levels are greatly reduced, mitotic figures (arrows) are numerous, nuclei are enlarged 
(arrowheads), and hepatocytes appear swollen. Bar, 50 mm; X 563. 90 
Figure 4.6.  Trout liver section after seven days on 0.18% dietary DHEA. Mitotic 
activity (open arrows) remains high, nuclear atypic (arrowheads) are prominent, increased 
numbers of small cells (nuclei) (solid arrows) appear in cenu-otubular locations, and a 
biliary ductule is present. Bar, 50 mm; X 563. 91 
Figure 4.7.  Trout liver section after 14 days on 0.18% dietary DHEA. Most hepatic 
tubules contain numerous biliary cells (solid arrows) forming bile ductules. Residual 
hepatocytes are swollen, mitotic figures (open arrows) still common. Bar, 50 mm; X 563. 92 
Figure 4.8.  Trout liver section 21 days after onset of dietary 0.18% DHEA. Residual 
hepatocytes have prominent intercellular spaces, nearly all tubular profiles have biliary cells 
(solid arrows) streaming from the central region. Bar, 50 mm; X 563. 93 
Ultrastructural Changes 
Electron microscopy revealed dramatic cellular changes in livers of DHEA-treated 
animals (Fig. 4.10-4.16). Cytoplasmic clefts, possibly resulting from crystalline inclusion 
bodies are present in both hepatocytes and biliary cells. The hepatomegaly does not appear 
to be due to peroxisome proliferation, instead hepatocytes are packed with rough 
endoplasmic reticulum (RER). Vacuoles containing very low density lipoprotein (VLDL ) 
-like material associated with golgi and areas of vesiculation of RER indicate that 
hepatocytes are producing a secretory protein. Other changes include nuclear folding and 
cellular swelling. 94 
Figure 4.9.  Transmission electron micrograph of liver obtained from 6-month old 
rainbow trout. Hepatocytes are polygonal shaped with distinct cell boundaries (arrows) 
and round-to-oval nuclei (N). Cytoplasmic organelles usually have a perinuclear 
compartmentalized orientation and large peripheral deposits of glycogen (G). Biliary cells 
(B) have indented nuclei and sparse cytoplasmic organelles. X 2600. 95 
Figure 4.10.  Micrograph of trout liver following treatment with 0.18% dietary DHEA 
for two days. Hepatocyte (H) demonstrates a clear cleft (arrowhead) within a lysosome, 
which is suggestive of a cholesterol crystalline inclusion, adjacent lysosomes (Ly), and 
numerous lipid droplets (L). Hepatocytes also appear to have slightly decreased amounts 
of glycogen (G) deposits. Biliary cells (B) have clear cytoplasmic clefts (C). X 3300. 96 
Figure 4.11.  Micrograph of trout after four days on 0.18% dietary DHEA. 
Hepatocytes show evidence of toxicity because of the marked variation in cell shape 
(elongated to swollen), areas of vesiculation of RER (*) and reduplication of basement 
membranes (arrows). X 4100. 97 
Figure 4.12.  Micrograph of trout after four days on 0.18% dietary DHEA.. Note 
vacuoles (arrows) containing VLDL protein-like material associated with golgi, areas of 
vesiculation of RER (*) and a lysosome containing clear clefts. X 6500. 98 
Figure 4.13.  This low power micrograph of trout liver after seven days on 0.18% 
DHEA shows destruction of liver architecture because of the marked variation in hepatocyte 
shape, absence of glycogen, large cytoplasmic vacuoles, and filling of the cytoplasm with 
RER. Degenerate hepatocytes (DH) appear to contain numerous clear clefts Biliary cell 
(B). X 2600. 99 
Figure 4.14.  Micrograph of trout liver after seven days on 0.18% DHEA. Note the 
atypical cellular centers composed of biliary cells (B), macrophages (M) and degenerate 
hepatocytes (DH). X 2600. 100 
Figure 4.15.  Micrograph of trout liver following 14 days of dietary exposure to 0.18% 
DHEA. The nuclear envelopes of hepatocytes (H) and biliary cells (B) are invaginated or 
indented. The cytoplasm of hepatocytes are usually filled with RER (*). X 2600. 101 
Figure 4.16.  Micrograph of trout liver after 21 days of exposure to 0.18% DHEA. Note 
the cluster of degenerate hepatocytes (DH) that have marked folding and invagination of 
their nuclear envelopes. These hepatocytes also display large cytoplasmic clear clefts and 
have distorted, irregular shapes. Adjacent hepatocytes display large autophagocytic 
vacuoles (V). X 6500. 102 
The histological and ultrastructural changes indicate that the liver enlargement 
produced by DHEA treatment does not result from peroxisome proliferation. Instead, a 
combination of proliferation of biliary preductule cells and hepatocyte swelling (due to 
increases in RER) appears to be responsible. PCNA was used as an additional measure of 
cell proliferation. Levels of PCNA in liver homogenates were increased by 4, 7, or 14 
days of DHEA treatment (Fig. 4.17). 
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Figure 4.17.  Western blot analysis of liver homogenates probed with antibody to 
proliferating cell nuclear antigen (PCNA). 
Ultrastructural examination of hepatocytes indicates that these cells are producing a 
secretory protein. Serum vitellogenin levels were measured to determine if this yolk 
protein precursor was the protein being secreted by the liver. Vitellogenin levels increased 
from nondetectable in serum of control trout (limit of detection = 2.5 iig/m1) to greater than 
3 mg/ml in serum of trout fed 0.18% DHEA for 14 days. X 
103 
400
 
y = 276.772x + 86.899
 
r2 = 0.909
 
300
 
X
 
200
 
a) 
5 100
 
5  10
 
Time (days) of DHEA
 
Figure 4.18.  Serum vitellogenin levels in trout fed 0.18% DHEA.  Symbols represent 
vitellogenin levels in each of two pooled blood samples per time point. 
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DISCUSSION
 
Dietary DHEA effectively raised serum DHEA to levels comparable to human 
DHEAS levels (20). In DHEA-fed trout, however, circulating levels of DHEA and 
DHEAS are approximately equal, while in humans the ratio of DHEAS to DHEA is about 
100:1 (21). Serum DHEA levels rose sharply for the first two days of treatment then 
decreased. This decline may repiesent enhanced metabolism of the steroid or could be due 
to increased binding to serum proteins. 
A transient increase in palmitoyl CoA oxidation (1.9-fold) occurred with this 
treatment, but to a lesser extent than that reported with rodents. Male Wistar rats treated 
with 300 mg DHEA/kg body weight for 14 days had a 7.9-fold increase in peroxisomal B-
oxidation and a 1.6-fold increase in catalase activity (22). In contrast to the response in 
rats, peroxisomal catalase activity was significantly decreased in trout fed DHEA. 
In rodents, peroxisome proliferators also induce levels of cytochrome P450s 
responsible for co-hydroxylation of fatty acids. In male Sprague-Dawley rats, dietary 
DHEA (0.45% for 7 days) increased co-hydroxylation of lauric acid 17-fold (4). DHEA at 
100 mg/kg/day for four days increased cytochromes P4504A protein and mRNA levels by 
20-fold (5). In this experiment, we did not observe any co-hydroxylation of lauric acid and 
hydroxylation at other positions was not significantly increased at any timepoint. The 
separation conditions used for this experiment did not distinguish between the co-1 through 
w -6 hydroxylated products, so we cannot rule out the possibility of changes in the ratios of 
these hydroxylated products. 
Total cytochrome P450 content was decreased by dietary DHEA treatment. In 
trout, as in mammals, treatment with androgens and estrogens have opposite effects on 
hepatic cytochrome P450 levels, with estrogens increasing and androgens depressing 
specific content (23, 24). In mammals, DHEA serves as a precursor of both androgens 105 
and estrogens (25). The decrease in total P450 levels in trout may indicate that DHEA has 
more of an androgenic than estrogenic effect in this model. 
A third marker of peroxisome proliferation in rodents is hepatomegaly, the result of 
increased numbers and size of peroxisomes. Trout fed DHEA for 4-14 days had 
significantly elevated liver somatic indices compared to controls. The hepatomegaly 
observed with DHEA treatment of trout, however, does not appear to be due to peroxisome 
proliferation. Instead, it results from a combination of cell proliferation and hepatocyte 
enlargement. The proliferating cells appear to be biliary preductule cells, although the 
tumors produced by DHEA treatment are primarily mixed carcinomas and hepatocellular 
carcinomas. The existence of a liver stem cell, capable of differentiating into either 
hepatocytes or bile ductule cells has been proposed (26, 27). Recently it was demonstrated 
that cultured oval cells derived from carcinogen-treated rats exhibit properties of both 
hepatocyte and biliary cells (28). If the cells induced to proliferate by DHEA treatment are 
actually undifferentiated precursor or stem cells, then this could explain the tumor outcome. 
This preductule hyperplasia may also be the cause of the cholestasis and increases in serum 
bilirubin levels observed in DHEA treated trout. 
The ultrastructural changes, including proliferation of rough endoplasmic reticulum, 
vesiculation of endoplasmic reticulum, mitochondrial swelling, and decreased glycogen 
indicate that there is production of a secretory protein. Similar changes have been reported 
as part of the normal reproductive cycle in mature female rainbow trout during the period of 
exogenous vitellogenesis (29). We found that DHEA treatment dramatically induced serum 
levels of the glycolipophosphoprotein vitellogenin in juvenile trout. Induction of this yolk 
protein precursor is mediated by the estrogen receptor, however, high doses of androgens 
have also been shown to increase its production in fish (30, 31). Ultrastructural 
examination of DHEA-treated fish revealed cytoplasmic clefts, possibly resulting from 
crystalline inclusion bodies. Secretory granules containing yolk-like crystalline structures 
have been reported in the liver of estradiol-treated goldfish (30). Many of the 106 
ultrastructural changes observed with DHEA treatment appear to be due to the conversion 
of DHEA into androgens and/or estrogens. 
Multi lamellar lipid-like structures were observed in some hepatocytes from DHEA-
fed trout. Myelin figures have been reported in cultured human epithelial cells treated with 
DHEA (32, 33). These structures may be related to DHEA's effects on lipid metabolism. 
Although DHEA has been shown to have anti-atherogenic and anti-obesity properties, its 
effects on serum cholesterol are mixed.  In this experiment, cholesterol levels were 
increased by DHEA treatment. Loria et al. (34), found that the effects of dietary DHEA on 
cholesterol in C57BL/6J mice were dependent on diet, with DHEA lowering plasma 
cholesterol in mice fed a standard semipurifed diet and raising it in animals fed a 
hyperlipemic diet (1% cholesterol and 0.5% cholic acid added). Our diet resembles the 
hyperlipemic diet in that it contains 10% salmon oil and 0.35% choline (10). In addition, 
the observed increases in serum cholesterol might be related to the increases in vitellogenin 
because about 10% of the lipid content of rainbow trout vitellogenin is cholesterol (35). 107 
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ABSTRACT
 
Dehydroepiandrosterone (DHEA) is an adrenal steroid with chemoprotective effects 
against a wide variety of conditions including cancer, obesity, diabetes, and cardiovascular 
disease. However, DHEA is also a carcinogen in laboratory animals, possibly through its 
function as a precursor of sex steroids or through peroxisome proliferation. The structural 
analog, 16a-fluoro-5-androsten-17-one (8354) has been reported to have enhanced 
chemopreventive activity without the steroid precursor and peroxisome proliferating effects 
of DHEA. This study compares DHEA and 8354 in rainbow trout, a species that is 
resistant to peroxisome proliferation but is highly susceptible to the carcinogenic and tumor 
enhancing effects of DHEA. Trout were exposed as fry to aflatoxin B1 (AFB1) or given a 
sham exposure, then were fed diets containing 444 ppm DHEA or 8354 for six months. 
Post-initiation treatment with DHEA significantly increased liver tumor incidence, 
multiplicity, and size compared to initiated controls. The analog 8354 slightly increased 
tumor incidence (p<0.06) but had no effect on multiplicity or size. Six percent of trout 
treated with DHEA alone developed tumors, while no tumors occurred in non-initiated trout 
fed control or 8354 containing diets. Serum levels of androstenedione were elevated by 
DHEA- (48-fold) or 8354- (6-fold) treatment. Serum B-estradiol titers were increased in 
DHEA- but not 8354-treated trout. Vitellogenin was induced significantly by either DHEA 
(434-fold) or 8354 (21-fold). Peroxisomal B-oxidation was not increased by either 
compound and catalase activity was decreased in DHEA-treated animals. This research 
suggests that in rainbow trout the tumor enhancing effects of DHEA may be due to its 
function as a sex steroid precursor and are unrelated to peroxisome proliferation. These 
carcinogenic properties are reduced in the analog 8354 which has been advocated as an 
alternative to DHEA for chemoprevention. 112 
INTRODUCTION
 
Dehydroepiandrosterone (DHEA), is the major circulating hormone in human 
plasma. This adrenal steroid is secreted in a pattern that peaks in early adulthood, then 
declines with age (1). The function of DHEA is largely unknown except as a precursor of 
other hormones. Low levels of DHEA have been associated with a number of disease 
conditions including breast cancer (2), bladder cancer (3), lung cancer (4), HIV, and 
Alzheimer's disease (5). In animal models, DHEA has been shown to be protective 
towards a wide variety of conditions including atherosclerosis, diabetes, obesity, and 
cancer (6). The cancer chemoprotective effects of this compound may be due to its action 
as an inhibitor of glucose-6-phosphate dehydrogenase (G6PD) with subsequent depletion 
of NADPH and ribose-5-phosphate intermediates (7). 
DHEA, however, has several properties that limit its use as a chemopreventive 
agent. DHEA is a precursor for androgens and estrogens and, in human clinical trials has 
been shown to increase androgen levels in female subjects (8, 9). In addition, DHEA is a 
peroxisome proliferator (10-12) and rodent carcinogen (13). Exposure to peroxisome 
proliferators leads to increases in the number and size of peroxisomes, hepatomegaly, and 
induction of peroxisomal and microsomal enzymes involved in fatty acid metabolism (14, 
15). Prolonged exposure to peroxisome proliferators results in hepatocarcinogenesis in 
some species. Rats and mice are particularly sensitive to the peroxisome proliferating 
effects of these compounds, whereas, primates appear to be relatively resistant (16). A 
recent review concluded that peroxisome proliferators are a discreet class of non-genotoxic 
rodent-specific carcinogens with little potential as hepatocarcinogens in humans, and 
therefore, the risk to humans was judged to be insignificant (17). 
We have recently shown, however, that DHEA is also carcinogenic in rainbow 
trout (18), a species that resembles humans in being relatively insensitive to peroxisome 
proliferation (19, 20). Trout are particularly sensitive to the carcinogenicity and tumor 113 
enhancing effects of DHEA, despite being insensitive to its peroxisome proliferating 
effects. DHEA is carcinogenic in trout at doses 20-fold lower than the dose which is 
hepatocarcinogenic in rats. It is possible that the carcinogenicity of DHEA is related to the 
capacity of this compound to be metabolized to androgens and estrogens, rather than as a 
peroxisome proliferator. 
The DHEA structural analog 16a-fluoro-5-androsten-17-one (8354) is reported to 
maintain many of the chemoprotective effects of DHEA with minimal side effects (21). 
This analog is a stronger inhibitor of G6PD activity than DHEA but does not appear to be 
readily metabolized to androgens and estrogens, or cause peroxisome proliferation in 
rodents (22). DHEA analog 8354 had protective effects similar to DHEA against N­
methyl-N-nitrosourea-induced mammary carcinogenesis (23), was protective towards 
colon and small intestine cancer in azoxymethane-initiated male F344 rats (24), and was 
more potent as an inhibitor of dimethylbenz[a]anthracene-initiated, tetradecanoylphorbol­
acetate-promoted skin papillomas than was DHEA (25). In addition to its cancer 
chemoprotective effects, 8354 also reduced hyperglycemia without causing any increase in 
seminal vesicle weight in insulin-resistant diabetic mice (26). 
This study compares the effects of dietary 8354 with those of DHEA towards 
AFB1- initiated hepatocarcinogenesis in rainbow trout. As in mammals, 8354 had a much 
lower capacity to be metabolized to androgens and estrogens than DHEA. The analog 8354 
was not hepatocarcinogenic at the dose level used in this study and had only slight 
enhancing effects on AFBI-initiated carcinogenesis. DHEA, as previously reported was a 
complete carcinogen and dramatically enhanced AFBi hepatocarcinogenesis. 114 
MATERIALS AND METHODS
 
Materials 
DHEA analog 8354 was provided by Dr. Arthur G. Schwartz (Temple Univ., 
Philadelphia, PA). The vitellogenin antibody and standards were provided by Dr. David 
R. Idler (Memorial Univ. of Newfoundland; St. John's, Newfoundland, Canada). 
Proliferating cell nuclear antigen (PCNA) antibody was purchased from Paracelsian 
(Ithaca, NY). Western blotting reagents were obtained from Biorad (Hercules, CA). 
DHEA, AFB1 and other reagents were purchased from Sigma Chem. Co. (St. Louis, MO). 
Animals and treatments 
This paper describes the results of two studies, a nine month tumor study and a 
two-week short-term experiment. Rainbow trout (Oncorhynchus mykiss) were hatched 
and reared at the Oregon State University Food Toxicology and Nutrition Laboratory. The 
tumor study used 800 animals; 500 of these were initiated as fry (75 days post-spawning) 
by a 30 min water bath exposure to 10 ppb AFB1. The remainder were given a sham 
exposure (30 min in 0.01% ethanol). For the first three months after initiation, trout were 
fed Oregon Test Diet (OTD), a semi-purified, casein-based diet (27). Trout were then 
divided into experimental groups and fed modified OTD diets containing 444 ppm (w/w) 
DHEA or 8254 until the conclusion of the study 42 weeks after initiation. The modified 
OTD contained less vitamin E (100 mg/kg) than standard OTD but was still above the levels 
required for normal growth (28). Once on experimental diets, trout were fed ad lib (2.8­
5.6% body wt.), five times per week. Each treatment group contained 100-120 trout, 
housed 50-60 per tank in duplicate 100 gal continuous flow tanks (4 tanks of initiated 
controls were used). Trout were deep :y anaesthetized by an overdose of MS-222 nine 
months post-initiation while still sexually immature. Blood was drawn from the caudal 
vein and then livers were removed and examined. Livers were fixed in Bouin's solution 115 
for future histological examination. In the short-term study, 36 fish, each weighing 
approximately 100 g were distributed into three two-foot tanks and fed one of the above 
experimental diets daily for 14 days. 
Enzyme assays 
Trout liver peroxisomal B-oxidation and catalase activities were measured after two 
weeks of dietary DHEA or 8354. Animals were stunned by a blow to the head and killed 
by decapitation. This is an acceptable method of euthanasia according to the 1993 report of 
the AVMA.panal on euthanasia (29). Livers from four fish per diet were immediately 
removed and placed in 60 mM Tris, 0.25 M sucrose buffer (pH 8.3). Livers were 
homogenized, centrifuged at 600 g for 20 min (4°C), and the supernatant was centrifuged 
at 12,000 g (4°C) for 30 min to obtain the mitochondrial/peroxisomal fraction. The 12,000 
g pellet was resuspended and protein concentration determined by the method of Lowry et 
al., using bovine serum albumin as a standard (30). Peroxisomal B-oxidation of palmitoyl-
CoA was measured (in triplicate) by spectrophotometrically monitoring the reduction of 
NAD+ to NADPH at 340 nm in the presence of cyanide (31, 32). Catalase activity was 
determined by measuring the decomposition of hydrogen peroxide spectrophotometrically 
at 240 nm (33). 
G6PD activity was measured in whole blood obtained from trout fed control diet, 
DHEA, or 8354 for two weeks. The assay, which measures the production of NADPH 
from NADP in the presence of glucose-6-phosphate, was conducted using a Sigma 
diagnostic kit according to manufacturer's instructions except that incubations were 
performed at 30 rather than 37° C. Results were normalized to hemoglobin concentrations. 
Electrophoresis and Immunoblotting 
PCNA levels were determined in liver homogenates from the two-week experiment 
(prepared in 60 mM tris, 0.25 M sucrose buffer as described above). Proteins were 116 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 
10% acrylamide gels (34) and electrophoretically transfered to nitrocellulose (Biorad Trans-
Blot®). Blots were probed with a mouse monoclonal antibody to rat PCNA followed by a 
horseradish peroxidase-linked secondary antibody and proteins detected by 
chemiluminescence (Amersham Corp., Arlington Heights, IL). Western blots were 
scanned on a flatbed scanner (HP Scan Jet llcx) and analyzed on a Power Macintosh 7100 
with the public domain software NIH Image version 1.54 (written by Wayne Rasband at 
the U.S. National Institutes of Health and available from the Internet by anonymous ftp 
from zippy.nimh.nih.gov). 
Serum Hormones 
Serum B-estradiol and androstenedione were determined by radioimmunoassay 
(Wein Laboratories, Succasunna, NJ) according to manufacturer's instructions except that, 
for the B-estradiol assay, extractions were performed in ethyl acetate: hexane (3:2), isotope 
concentrations were halved, and antibody concentrations were decreased by three-quarters 
in order to increase sensitivity. Under these conditions, the lower limit of detection was 10 
Clinical Chemistry 
Serum cholesterol, albumin, and serum glutamic-oxaloacetic transaminase (SGOT) 
were analyzed on a Ciba Corning 550 Express Clinical Chemistry Analyzer using 
manufacturer's protocols and reagents. Packed cell volume was determined by 
centrifugation. Serum vitellogenin was measured with an enzyme linked immunosorbent 
assay (35). 117 
Statistical analysis
 
Differences in tumor incidence were assessed using Fisher's exact test (two-tailed). 
Body weights, liver weights, clinical values, and tumor size were log transformed and 
compared by ANOVA followed by the Scheffe's test for pairwise comparisons. The 
nonparametric Kruskal-Wallis test was employed to compare the average number of tumors 
per animal in trout with tumors using chi-square approximation of p-values. All statistical 
analyses were performed in SAS version 6.04 (SAS Institute, Cary, NC). 118 
RESULTS
 
Dietary DHEA was a complete carcinogen in trout. Six percent of the sham-
initiated trout fed 444 ppm DHEA developed liver tumors. No tumors occurred in sham-
initiated animals given either control diet or 444 ppm 8354. Tumor incidence was ten-fold 
higher in AFB1- initiated trout fed DHEA than in initiated trout fed control diet (p < 0.0001) 
(Fig. 5.1). 
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Figure 5.1.  Liver tumor incidence and multiplicity in sham and AFB1-initiated trout fed 
control, 444 ppm DHEA, or 444 ppm 8354. Tumor incidence (bar height) and multiplicity 
(patterns) were determined by gross examination at the time of euthanasia and confirmed by 
hand slicing of fixed tissues. * indicates tumor incidence significantly different from 
noninitiated controls (p < 0.05). ** indicates tumor incidence and multiplicity significantly 
different from initiated controls (p < 0.0001). # indicates trend towards significance (p = 
0.06) in tumor incidence. 119 
Tumor size and multiplicity were also enhanced by DHEA treatment. The average 
tumor size (± SEM) in initiated controls was 1.7 ± 0.4 mm and the average number of 
tumors per tumor bearing animal was 1.2 ± 0.1. In initiated trout treated with DHEA the 
average tumor size was 2.7 ± 1.7 and multiplicity was 2.9 ± 0.2. Tumor incidence was 
slightly higher in animals treated with 444 ppm 8354 (p < 0.06). The analog had no 
significant effects on tumor size (1.7 ± 0.2) or multiplicity (1.3 ± 0.2). 
Peroxisomal 13-oxidation and catalase activity were measured after two weeks on 
experimental diets to determine the extent of peroxisome proliferation (Fig. 5.2). Neither 
compound altered cyanide insensitive palmitoyl CoA oxidation. In contrast to the 
enhancing effects of DHEA on catalase activity in rodents (36), DHEA treatment in trout 
decreased peroxisomal catalase activity. We have also observed dose-dependent decreases 
in catalase activity in trout fed DHEA for 29 weeks (Chapter 2). Analog 8354, as in 
rodents, had no effect on this enzyme. These results are consistent with previous studies 
indicating that trout are relatively insensitive to peroxisome proliferation (19, 20). 
G6PD activity was measured in red blood cells of trout fed experimental diets for 
14 days. In contrast to what has been reported in rodents, G6PD activity was not inhibited 
by DHEA or 8354 (Fig. 5.3). 120 
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Figure 5.2.  Peroxisomal 13-oxidation (left axis) and catalase activity (right axis) after 
two weeks of experimental diets. Each bar represents the mean (+ SEM) of palmitoyl CoA 
oxidation or catalase activity in four trout.  Activities were measured as described in 
Materials and Methods. 
Serum androstenedione and 13-estradiol levels were measured at the conclusion of 
the tumor study in order to monitor the potential for DHEA and the analog to be converted 
into other steroids (Fig. 5.4). Male and female trout of this age have very low titers of 
androgens or estrogens (37). Levels of androstenedione were determined to be elevated 
over 40-fold by DHEA treatment, however because the antibody used for this RIA has 
some cross reactivity with DHEA, part of this increase may represent serum DHEA levels 
(1 ng DHEA = 55 pg androstenedione equivalent). Androstenedione was also elevated by 
8354 treatment (6-fold). 13-estradiol levels were significantly elevated by DHEA (3-fold) 121 
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Figure 5.3.  G6PD activity after two weeks of experimental diets. Each bar represents 
the mean (+ SEM) of G6PD activity in four trout. Activity was measured as described in 
Materials and Methods. 
but not by compound 8354. Levels of vitellogenin, a yolk protein induced by B-estradiol 
were increased from nondetectable (limit of detection of 2.5 gg/m1) to 50 µg/ml in the 8354 ­
treated trout and to more than 1 mg/m1 in the DHEA-treated animals. Both treatments 
resulted in a higher incidence of maturing males than in the control group (data not shown). 
Some toxicity was observed in animals fed either DHEA or 8354 (Table 5.1). The 
average body weight at the conclusion of the tumor study was significantly lower in 
animals fed either DHEA or 8354 than in those fed control diets. There were no significant 
differences in body weights between sham and AFB1-initiated trout fed the same diets 
(therefore, only the data from sham-initiated trout are shown). The percentage of body 
weight made up by liver was twice as high in the DHEA-fed compared to control fish. 122 
Liver somatic indexes in 8354-fed trout were 25% higher than in control animals. The 
increases in relative liver weight are partly due to the lower body weights, however 
absolute liver weights were also significantly higher in the DHEA-fed trout despite the 
lower body weights (Table 5.1). Livers of animals fed DHEA or 8354 for two weeks had 
higher levels of PCNA than untreated animals (6-fold and 3-fold respectively) (Fig. 5.5) 
indicating that cell proliferation is involved in the liver enlargement. 
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Figure 5.4.  Serum androstenedione (ng/dl) and 13- estradiol levels after 26 weeks on 
experimental diets. Each bar represents the mean (+ SEM) of the serum hormone levels of 
four individual animals. * indicates significantly different from controls 123 
Animals treated with DHEA or 8354 for 26 weeks had decreased packed blood cell 
volumes (Table 5.1). Hematocrits were lowest in the 8354-fed animals but were also 
significantly decreased by DHEA treatment. Serum cholesterol, albumin, and SGOT were 
all increased by DHEA treatment with values in the 8354-treated animals intermediate 
between control and DHEA-treated animals. No significant mortality was associated with 
any of the treatment groups. 
Table 5.1. Clinical Parameters in Non-inititated Trout Fed Control, DHEA or 8354 Diets. 
Treatment 
Control  444 ppm DHEA  444 ppm 8354 
Number of Animals  98  101  92 
Body Weighta (g)  94.84b ± 2.90  80.89c ± 2.61  70.17b ± 2.97 
Liver Weight (g)  0.69b ± 0.02  1.33c ± 0.04  0.73b ± 0.03 
Liver Somatic Index (%)  0.74b ± 0.01  1.66c ± 0.03  1.04d ± 0.02 
Hematocrite (%)  34.50b ± 1.19  27.25c ± 1.32  20.75d ± 1.11 
Cholesterol (mg/dl)e  88b + 27  383c ± 31  248d + 9 
Albumin (g/d1)e  0.98b ± 0.33  2.98c ± 0.15  2.10b,c ± 0.40 
SGOT (IU/L)e  243 ± 86  462 ± 38  359 ± 70 
Vitellogenin (i.tg/m1)e  <2.5b  1086c ± 88  53d ± 14 
aValues are means ± SEM. Numbers in the same row bearing different superscripts are
 
significantly different from one another (p < 0.05).
 
eValues are means ± SEM of 4 samples per treatment.
 124 
127 Densitometry 
96
 
68
 
22 19  18
 
I 1  II
 I
 
OTD  DHEA  8354
 
Figure 5.5.  Western blot of trout liver homogenates probed with antibody against rat
 
PCNA. Lanes 1-3 are from control animals, 4-6 from animals treated with 444 ppm
 
dietary DHEA for 14 days, and 7-9 from trout treated with 444 ppm dietary 8354 for 14
 
days. Each lane contains 15 lig protein from liver homogenates.
 125 
DISCUSSION
 
DHEA is  a promising chemopreventive agent, however the potential of this 
compound for human use is limited by its role as a precursor for sex steroids and its 
carcinogenic effects. In rats, the hepatocarcinogenicity of DHEA has been attributed to 
peroxisome proliferation (13), a mechanism which may have little or no relevance towards 
humans (17). However, we have demonstrated that DHEA is  also a carcinogen in rainbow 
trout, a species which responds only weakly to peroxisome proliferators. Trout are quite 
sensitive to the carcinogenic and tumor promoting effects of DHEA with dietary doses as 
low as 222 ppm for 30 weeks significantly enhancing AFB 1-initiated hepatocarcinogenesis 
(18). In the current study we use this highly sensitive model to compare the tumor 
modulating effects of DHEA  with those of its structural analog 8354. 
Limited quantities of 8354 were available, therefore only a single dose level was 
tested. We selected a DHEA dose which had previously been shown to produce a 
moderate incidence of tumors in animals treated with DHEA alone, and to markedly 
enhance AFB1-initiated hepatocarcinogenesis. This dose, however did have some toxicity 
associated with it as hematocrits were decreased, and cholesterol and albumin levels 
increased by these experimental diets. The decreased hematocrits do not appear to be due 
to inhibition of G6PD,  as the activity of this enzyme in red blood cells was not decreased 
by DHEA or 8354 treatment. Both DHEA  and 8354 decreased trout weight gain compared 
to animals on control diet. This was not unexpected because DHEA has received 
considerable attention for its antiobesity properties (38). Compound 8354 has previously 
been shown to be more effective than DHEA  in reducing weight gain in BALB/cJ  mice (22) 
and this appears to be true in trout as well. 
The dose of DHEA employed in this study strongly enhanced AFBvinitiated 
carcinogenesis, producing increases in tumor incidence, tumor size, and tumor multiplicity, 
and also was a complete carcinogen in this model. In contrast, the analog did not produce 126 
tumors when fed to sham-initiated trout. In AFB1- initiated trout, tumor incidence was 
slightly higher in the 8354-treated animals than in fish fed control diet, however this 
difference was not statistically significant (p = 0.06). Tumor size and multiplicity were not 
enhanced by treatment with the analog. The markedly different effects of these two 
compounds on carcinogenesis in trout supports the hypothesis that conversion of DHEA to 
sex steroids plays an important role in its biological effects. 
Although trout are weak responders to peroxisome proliferators, we cannot rule out 
the possibility that DHEA carcinogenicity in trout is linked to its peroxisomal effects. In 
trout, dietary DHEA did not change peroxisomal 13- oxidation but decreased peroxisomal 
catalase. Treatment with 8354 had no effect on either activity. One proposed mechanism 
for the carcinogenicity of peroxisome proliferators is based on the differential induction of 
hydrogen peroxide generating and degrading enzymes and resultant oxidative stress (39, 
40). Even though the hydrogen peroxide generating pathway of peroxisomal B-oxidation 
was not increased in trout, DHEA treatment decreased catalase activity, a situation that may 
have resulted in a pro-oxidant condition. Hepatomegaly is one of the classic markers of 
peroxisome proliferation in rats and mice. DHEA, and to a lesser extent 8354, caused 
enlarged livers in trout as well. Histological and ultrastructural studies of livers of DHEA-
treated trout in a previous study suggested that the liver enlargement was not due to 
peroxisome proliferation, but instead may be due to androgenic or estrogenic effects (41). 
In the current study, the liver somatic indices were significantly higher in DHEA- than in 
8354-treated animals and correlated well with the intracrine and tumor enhancing effects of 
the two compounds. 
In mammals, DHEA serves as a precursor of both androgens and estrogens (42). 
Although circulating levels of DHEA and the sulfate are quite low in trout, a trout 313­
hydroxysteroid dehydrogenase A5-4-isomerase has recently been cloned which, in vitro, 
has high activity for the conversion of DHEA to androstenedione (43). We found that 
dietary DHEA-administration significantly elevated serum androstenedione and B-estradiol. 127 
These steroids were only slightly elevated in trout fed 8354, so it appears that in trout, as in 
mammals, 8354 is considerably less effective as a sex steroid precursor than DHEA. 
Further support for this comes from serum levels of the estrogen-inducible yolk protein 
vitellogenin. Vitellogenin was induced over 4.00-fold in animals treated with DHEA, but 
only about 20-fold in 8354-treated animals. Vitellogenin levels in DHEA-treated fish were 
higher than would be predicted from the serum estradiol levels (44), however high 
androgen doses have also been shown to induce vitellogenin in some fish species (45, 46). 
Limited conversion of 8354 to estrogens and androgens could explain why this compound 
is considerably less effective at enhancing AFBI carcinogenesis in trout than DHEA. B­
estradiol has been shown to be a potent tumor promoter in this model (47). If the 
carcinogenic and tumor enhancing effects of DHEA are due to its steroid precursor 
properties, then this mechanism could be relevant to humans. 128 
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ABSTRACT
 
Dehydroepiandrosterone (DHEA) is a strong enhancer of aflatoxin B1 (AFB i) 
hepatocarcinogenesis in trout, producing increases in tumor incidence, tumor multiplicity, 
and tumor size when administered after carcinogen exposure. This paper describes studies 
examining the effects of DHEA on the time to tumor development, and the modulation of 
carcinogenesis when DHEA is given prior to and during AFB1 exposure. In the first 
experiment, trout were initiated by a 30 min water bath exposure to 10 ppb AFB 1. Three 
months post-initiation, animals were started on either control diet or diet containing 444 
ppm DHEA. Fifty trout per treatment were sampled prior to the start of experimental diets, 
and then at monthly intervals for the next seven months and examined for the presence of 
tumors. Tumors were not detected in initiated controls until seven months after initiation. 
In initiated trout fed DHEA, the first tumor was detected five months after initiation (after 
just two months of dietary DHEA). Six months post-initiation, twenty percent of the 
AFB1- initiated trout fed DHEA had tumors, while no tumors were visible in either AFB1­
initiated controls, or noninitiated trout fed DHEA. This experiment shows that, in addition 
to increasing tumor incidence, tumor size, and tumor multiplicity DHEA also decreases 
tumor latency. The second experiment was designed to determine if the enhancing effect of 
DHEA on AFBi carcinogenesis is dependent on the time of DHEA administration relative 
to the time of AFBi exposure and if DHEA could be chemopreventive if administered prior 
to and concurrent with AFB1. Trout were fed one of two levels of DHEA (888 or 1776 
ppm) either prior to and during a four week initiation period of dietary AFBi 
administration, or for eight weeks following initiation with AFB 1. Nine months after 
initiation livers were examined for tumors. Neither exposure protocol provided protection 
towards AFBi hepatocarcingenesis. The strongest enhancement occurred when DHEA 
was fed during the postinitiation period. Levels of p53 and p34 cdc2 were decreased by 
DHEA treatment, indicating that DHEA may act through alterations in cell cycle control. 134 
INTRODUCTION
 
Dehydroepiandrosterone (DHEA) is an adrenal steroid that in animal models has 
been demonstrated to have chemoprotective properties towards a wide variety of conditions 
including atherosclerosis, obesity, diabetes, immune disorders, and cancer (1, 2). DHEA 
is protective towards both the initiation and promotion stages of cancer, possibly through 
its action as an inhibitor of glucose-6-phosphate dehydrogenase (3). DHEA, however, 
also causes hepatomegaly, proliferation of peroxisomes, and increases in peroxisomal !­
oxidation (4-9); characteristics of a group of nongenotoxic rodent carcinogens known as 
peroxisome proliferators (PPs) (10). Like other PPs, DHEA is a carcinogen in rats (11­
13), a species highly susceptible to both the peroxisome proliferating and carcinogenic 
effects of these compounds (14, 15). 
We have found that DHEA is also a hepatocarcingen in rainbow trout (16), a 
species which responds only weakly to PPs (17, 18). In addition, DHEA strongly 
enhanced aflatoxin B1 (AFB1) hepatocarcinogenesis in trout, causing increases in tumor 
incidence, tumor multiplicity, and tumor size when administered following AFBI 
treatment. These effects were largely independent of peroxisome proliferation with less 
than a two-fold increase in peroxisomal B-oxidation after 26 weeks on experimental diets 
(16). 
The studies described in this paper were undertaken to further characterize the 
enhancement of AFB1 carcinogenesis by DHEA. The first study examines the potential of 
DHEA to decrease the time to tumor appearance in AFB1-initiated trout. We have 
previously shown that DHEA enhances AFBI carcinogenesis, causing increases in tumor 
incidence, tumor multiplicity, and tumor size (16). A fourth measure of enhancement of 
carcingenesis is a decrease in tumor latency. The second experiment was designed to 
determine if DHEA enhancement of AFB  hepatocarcingenesis is dependent on the 
sequence of DHEA and carcinogen administration. Chemoprevention in one experimental 135 
protocol and enhanced carcinogenesis in another has been observed with other compounds. 
For example, the tumor modulator indole- 3- carbinol inhibits AFBI carcinogenesis when 
fed prior to and during carcinogen exposure, but promotes it when fed subsequently (19). 
Dietary DHEA has been shown to inhibit DNA binding of AFB1 to hepatic DNA of rats 
when fed for two weeks prior to AFBi treatment (20), therefore we felt it was possible that 
pretreatment of trout with DHEA could provide protection towards AFBI carcinogenesis. 
In this paper we report that, in addition to causing increases in tumor incidence, 
multiplicity, and size, postinitiation treatment with DHEA also decreases tumor latency in 
AFB 1- initiated trout. Treatment of trout prior to and during carcinogen administration 
increased AFBI hepatocarcingenesis, however the strongest enhancement occurred when 
DHEA was fed during the postinitiation period. Administration of DHEA for 8 or 12 
weeks produced alterations in the levels of p53 and p34 cdc2, proteins involved in the 
regulation of the cell cycle. The tumor enhancing and carcinogenic effects of DHEA may 
be related to its effects on cell proliferation and cell cycle control. 136 
MATERIALS AND METHODS
 
Materials 
DHEA (5-androsten-3b-o1-17-one) and AFB I were purchased from Sigma 
Chemical Co. (St. Louis, MO). Western blotting reagents were purchased from Biorad 
(Hercules, CO) and Amersham (Arlington Heights, IL). Antibodies to proliferating cell 
nuclear antigen (PCNA) and p34 cdc2 were obtained from Paracelsian (Ithaca, NY). 
Antibody to p53 was purchased from Oncogene Science, Inc. (Uniondale, NY). All other 
reagents were purchased from Sigma Chemical Co. (St. Louis, MO). 
Experimental Animals 
Rainbow trout (Oncorhynchus mykiss) were spawned and raised at the Food 
Toxicology and Nutrition Laboratory, Oregon State University. Animals were maintained 
at 12-14° in circular tanks with continuously flowing well water and alternating 12-hr light 
and dark cycles.  After spawning, trout were fed Oregon test diet (OTD), (21) until the 
start of the experiments. 
Experimental Designs 
Experiment 1. This experiment was designed to determine if treatment with 
DHEA decreased the time to tumor development in AFB1-initiated trout. Ten weeks after 
spawning, fry were given a 30-min water bath exposure to either 10 ppb AFBI or a vehicle 
control (0.02% ethanol). Trout were fed modified OTD (100 mg/kg vitamin E) for three 
additional months, then were placed into treatment groups (400 fish/tank, one 
tank/treatment) and fed either modifed OTD or the same diet containing 444 ppm DHEA 
(w/w). Twenty-five fish per treatment were sampled prior to the start of experimental diets 
(3 months post-initiation) and then fifty fish per treatment were sampled at monthly 
intervals for the next seven months (until 10 months post-initiation) (Fig. 6.1). 137 
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Figure 6.1.  Timecourse of DHEA enhancement of AFB1- initiated hepatocarcinogenesis 
(Experiment 1). 
Experiment 2. This experiment was designed to determine if pre- and co­
treatment of trout with DHEA relative to AFBi exposure would enhance or inhibit AFB 1­
initiated carcinogenesis. 
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Figure 6.2.  Time dependency of DHEA promotion of AFB1- initiated hepato­
carcinogenesis (Experiment 2). 
Five months after spawning, fry were placed into treatment groups (120 fish/tank, 
1 or 2 tanks/treatment) and started on a three phase dietary exposure protocol consisting of 
an eight week preinitiation phase, a four week initiation phase, and an eight week 
postinitiation phase (Fig. 6.2). During the preinitiation phase, animals were fed modified 
OTD (100 mg/kg vitamin E, rockfish oil base) containing 0, 888 or 1776 ppm DHEA 
(w/w). For the initiation phase, trout were fed diets containing the same levels of DHEA 
plus 0, 9, or 44 ppb AFB1. During the postinitiation phase, animals were given 0, 888, or 138 
Following the postinitiation phase, all animals were fed modified OTD for 30 weeks until 
the conclusion of the experiment. 
Electrophoresis and Immunoblotting 
Four fish per treatment were sampled at the end of each phase of experiment 2 in 
order to examine the effects of DHEA on cell proliferation and cell cycle control. Livers 
were removed, frozen in liquid nitrogen, and stored at -80° C until used. They were 
homogenized in ice cold sample buffer (10 mM potassium phosphate, pH 7.5, 20% 
glycerol, 0.1 mM EDTA, 0.2 mM PMSF) and protein concentrations determined according 
to Lowry et al. (22), using bovine serum albumin as standards. Proteins (20 4g/lane) were 
separated using polyacrylamide gel electrophoresis in the presence of sodium dodecyl 
sulfate (SDS-PAGE) (23) and electrophoretically transferred to nitrocellulose (Biorad 
Trans-Blote). Blots were probed with antibodies to p53 (Ab-3, mouse monoclonal), p34 
cdc2 (anti-mouse, rabbit polyclonal), and PCNA (anti-rat, mouse monoclonal). Blots were 
then probed with horseperoxidase-linked secondary antibodies and proteins detected by 
chemiluminescence (Amersham Corp., Arlington Heights, IL). 
Tumor Detection 
Trout were killed by an overdose of 3-aminobenzoic acid ethyl ester (MS-222) and 
livers removed and weighed. Livers were examined for tumors under a dissecting 
microscope, then were fixed in Bouin's solution for future histological examination. After 
48 hours livers were hand sliced to verify the presence of grossly observed tumors and to 
detect internal tumors. 139 
SCHEDULE 
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Figure 6.3.  Experimental groups of time dependency study (Experiment 2). 140 
RESULTS
 
Experiment I 
Treatment with DHEA decreased the growth rate of trout. Body weights were 
significantly lower in DHEA-fed animals beginning three months after the start of 
experimental diets and at each subsequent time point (Fig. 6.4). On the sixth month of 
experimental diets, the AFB 1- treated trout fed DHEA had significantly lower weights than 
sham-initiated trout fed DHEA, otherwise there were no significant differences in body 
weights between sham and AFB1- initiated animals. 
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Figure 6.4.  The effect of dietary DHEA on body weights. Values are means of 50 
measurements per treatment group at each timepoint except 3 months post-initiation when 
only 25 animals were sampled. 141 
110 
Post-initiation treatment with DHEA caused hepatomegaly. Both absolute (Fig. 
6.5) and relative liver weights (not shown) were significantly higher in the DHEA-treated 
compared to control-fed animals at each timepoint after the start of experimental diets. 
There were no significant differences in liver weights between sham and AFBI-initiated 
trout. 
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Figure 6.5. The effect of dietary DHEA on absolute liver weights. Values are means of 50 
measurements per treatment group at each timepoint except 3 months post-initiation when 
only 25 animals were sampled. 
Tumor incidence was enhanced by DHEA treatment (Fig. 6.6). At each timepoint 
beginning six months post-initiation, tumor incidence was significantly higher in AFB1­
initiated animals fed 444 ppm DHEA, than in initiated animals given control diet. In 
addition, tumors appeared sooner in the DHEA-fed trout. The first tumors appeared in 142 
AFB1- initiated/DHEA promoted animals five months after initiation (after two months of 
dietary DHEA). No tumors were detected in initiated control animals until seven months 
post-initiation. DHEA was also a complete carcinogen in this experiment, producing 2 and 
8 percent tumor incidences in sham-initiated trout receiving 444 ppm dietary DHEA for six 
and seven months, respectively. As expected, the spontaneous liver tumor incidence was 
quite low, with only one liver tumor observed in the 375 sham-initiated animals fed control 
diet. 
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Figure 6.6. The effect of dietary DHEA on liver tumor incidence (% of animals with liver 
tumors). Fifty animal were sampled at each timepoint except 3 months post-initiation when 
only 25 animals were sampled. 
In addition to increasing tumor incidence, DHEA treatment also increased tumor 
multiplicity (Table 6.1). There were significantly more tumors per liver in initiated trout 
fed DHEA than in tumor bearing animals which were fed control diet. Ten months after 
10 143 
initiation, the average number of tumors in initiated control trout was 1.1 ± 0.1 (± SEM). 
In initiated animals treated with DHEA the average number of tumors per liver was 4.0 ± 
0.5. The average tumor size was also larger in DHEA-treated animals at every timepoint, 
however, the differences in tumor size were not statistically significant in this experiment 
(Table 6.2). 
Table 6.1.  The effect of dietary DHEA on tumor multiplicity (expressed as average
 
number of tumors per liver in tumor bearing animals). * indicates significantly higher
 
tumor multiplicity than initiated controls (p 5 0.05).
 
Treatment  Months after Initiation 
5 6  7  8  9 10 
Sham/Control  0  0  1.0  0  0  0 
AFBi/Control  0  0  1.3  1.0  1.2  1.1 
Sham/DHEA  0  0  0  0  1.0  1.3 
AFBi/DHEA  2.0  1.1  2.0  2.5  2.2  4.0* 
Table 6.2.  The effect of dietary DHEA on average tumor size (mm diameter). 
Treatment  Months after Initiation 
5  6  7 8 9 10 
Sham/Control  0  0  1.0  0  0  0 i 
AFBi/Control  0  0  1.2  1.2  1.0  1.3
 
Sham/DHEA  0  0  0  0  2.0  1.3
 I 
AFB i/DHEA  0.5  1.4  1.9  1.7  2.0  2.2 1  1 i 
Experiment 2 
Treatment of noninitiated trout with 888 or 1776 ppm dietary DHEA for twelve 
weeks (during the preinitiation and initiation phases of experiment 2) produced significant 
increases in tumor incidence and multiplicity compared to controls (Fig. 6.7). 144 
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Figure 6.7.  Tumor incidence and multiplicity in noninitiated trout fed low (888 ppm) or 
high (1776 ppm) DHEA for 12 weeks (treatment 2 and 3) or high DHEA for 8 weeks 
(treatment 4). Treatments marked with different symbols (*) are significantly different 
from one another in tumor incidence and multiplicity (p < 0.05). Treatment numbers are 
from figure 6.3. 
Figure 6.8 shows tumor incidence and multiplicity in trout that were initiated with 9 
ppb dietary AFB I. Treatment with DHEA prior to, and during AFBI initiation increased 
tumor incidence and multiplicity, but only to levels approximating the additive effects of 
AFB1 and DHEA carcinogenicity. Postinitiation treatment significantly enhanced tumor 
incidence and multiplicity. 
Tumor incidences in animals initiated with 44 ppb dietary AFB1 were only slightly 
higher than in those initiated with 9 ppb AFB1 (Fig. 6.9). The pattern of enhancement by 
DHEA was similar to that observed with 9 ppb AFBI except that postinitiation treatment 145 
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Figure 6.8. Tumor incidence and multiplicity in trout initiated with 9 ppb AFB1. 
Treatments marked with different symbols (*) are significantly different in tumor incidence 
and multiplicity from one another (p < 0.05). Treatment numbers are from figure 6.3. 
with 888 ppm DHEA did not produce a significantly higher tumor incidence compared with 
pretreatment. 
At the end of each phase of the experiment the levels of PCNA, p53, and p34 cdc2 
were measured in order to determine the effects of DHEA on cell proliferation and cell cycle 
control. Figure 6.10 is a Western blot of trout liver homogenates from animals sampled at 
the end of the preinitiation period probed with an antibody to rat PCNA. After eight weeks 
of dietary DHEA, there are no treatment related differences in the levels of this antigen. 146 
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Figure 6.9.  Tumor incidence and multiplicity in trout initiated with 44 ppb AFBI. 
Treatments marked with different symbols (*) are significantly different in tumor incidence 
and multiplicity from one another (p < 0.05). Treatment numbers are from figure 6.3. 
Treatment # 
1 2  3 1 2 3  1 2 3 
Figure 6.10.  Western blot probed with antibody to PCNA. Lanes marked with #1 are 
from animals which were fed control diets, those marked with #2 were from trout fed 888 
ppm DHEA for eight weeks, and those marked with #3 were from trout fed 1776 ppm 
DHEA for eight weeks. 147 
Figure 6.11 shows Western blots which were probed with an antibody to p53 (Ab­
3). This antibody (under denaturing conditions) recognizes both mutant and wild-type p53 
in mammals. In control trout a double band of approximately 50 kDa reacts with this 
antibody. Treatment with DHEA for eight weeks (blot A) or twelve weeks (blots B and C) 
causes a dramatic decrease in these proteins in most, but not all trout. 
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Figure 6.11.  Western blots probed with antibody to p53. Blot A is from animals 
sampled at the end of the preinitiation phase. Blots B and C are from animals sampled at 
the end of the initiation period. Treatment numbers correspond to those in figure 6.3. 148 
Figure 6.12 is a Western blot probed with an antibody to p34 cdc2. Several 
proteins cross react with this antibody. One protein of approximately 34 kDa is decreased 
dramatically by 12 weeks of DHEA treatment. Another, of approximately 65 kDa appears 
to undergo a shift in molecular weight. 
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Figure 6.12.  Western blot probed with antibody to p34 cdc2. The blot contains proteins 
from liver homogenates from trout sampled at the end of the initiation phase. Treatment 
numbers correspond to those in figure 6.3. 149 
DISCUSSION 
Post-initiation treatment of AFB1-initiated trout with DHEA results in dose-
dependent increases in tumor incidence, multiplicity, and size (16). In this paper, we 
report that DHEA also decreases the latency period between initiation and the appearance of 
tumors. The first tumors were detected two months sooner in AFB i- initiated trout treated 
with 444 ppm DHEA than in initiated trout fed control diet. Six months post-initiation, 
twenty percent of animals initiated with AFB1 and fed DHEA for three months had tumors. 
No tumors were present in AFB1-initiated control trout or in sham-initiated trout fed DHEA 
for three months. At this timepoint, therefore, DHEA can be considered a promoter of 
AFB i- initiated hepatocarcingenesis. After seven months of dietary DHEA tumors occurred 
in animals treated with DHEA alone, as well as in AFB i- initiated controls. Combined, the 
two carcinogens have a synergistic effect. In this experiment, as previously reported, 
DHEA decreases the growth rate in trout (16). This compound has been extensively 
studied for its antiobesity properties (24, 25), therefore decreased weight gain may be an 
inappropriate measure of toxicity. This dose of DHEA also caused some additional effects 
which are probably related to the role of this compound as a precursor of androgens and 
estrogens (26). Most of the males in the DHEA-treated groups showed some signs of 
sexual maturation (secondary sex characteristics and developing testes). In addition, many 
of the DHEA-treated animals had a ragged appearance to their tails and fins. This may be 
the result of DHEA induction of vitellogenin. Previously we have observed that treatment 
of trout with DHEA causes dramatic induction of this calciuM-containing yolk protein 
precursor (27). Vitellogenesis causes mobilization of calcium from scales and other 
calcified tissues (28) and may be responsible for the damaged fins observed in this 
experiment. 
In the second experiment, DHEA failed to provide any protection towards AFB1­
initiated carcinogenesis when administered prior to and during carcinogen administration. 150 
It is still possible that treatment with DHEA before (but not during) carcinogen 
administration could have a protective effect, however this protocol was not examined in 
the current experiment. Treatment of animals with DHEA alone for twelve weeks was 
sufficient to produce tumors in four and eight percent of the animals fed 888 and 1776 ppm 
DHEA, respectively. This is of interest because nongenotoxic carcinogens do not generally 
produce tumors unless administered to an animal for most of its lifetime. There is some 
evidence that DHEA could have some genotoxic effects. In a previous study we found that 
about one-third of tumors examined from trout treated with DHEA had Ki-ras mutations 
(16). Mutations of this gene have not been detected in spontaneous liver tumors in trout, 
however due to the low spontaneous liver tumor incidence in trout of this age (0.1%), only 
a few tumors have been analyzed for ras mutations. 
The most dramatic enhancement of AFB1-initiated hepatocarcingenesis occurred 
when DHEA was fed during the postinitiation period. This may indicate that DHEA 
enhances carcinogenesis through stimulation of cell proliferation, or by providing a 
selective growth advantage to initiated cells. Antibodies to several proteins involved in cell 
proliferation and cell cycle control were utilized in this experiment. PCNA is an 
endogenous cell marker of DNA replication that is widely used for the measurement of cell 
replication. Animals treated with DHEA for eight weeks did not have higher levels of 
PCNA than control animals. Previously, we have found that PCNA levels increase during 
the first two weeks of DHEA treatment (29). After eight weeks of DHEA treatment, levels 
of this antigen are not elevated in liver homogenates however, this does not exclude the 
possiblity that certain cell populations are still rapidly dividing. 
The tumor suppressor p53 is involved in regulation of the cell cycle, control of 
DNA repair and initiation of apoptosis (30-32). Mutations in the p53 gene are the most 
frequently observed genetic alteration in human cancers (33). Animals deficient in p53 are 
highly susceptible to spontaneous tumors (34). The p53 gene in trout has been sequenced 
and found to be highly homologous with mammalian p53 (35). In this experiment we used 151 
an antibody which (under denaturing conditions) recognizes both mutant and normal 
mammalian p53. In blots of liver homogenates from control trout, this antibody reacts 
quite strongly with a double band of the approximate molecular weight of p53. Prolonged 
treatment with DHEA dramatically reduces levels of these proteins. 
The p34 cdc2 protein is one of a family of cyclin dependent kinases which are 
involved in the regulation of the cell cycle (36). High levels of this kinase have been 
demonstrated in animals treated with peroxisome proliferators (37). In contrast to these 
results, however, prolonged DHEA treatment of trout downregulates a protein of 
approximately 34 kDa which cross reacts to this antibody. Numerous proteins from trout 
liver homogenates cross react to this antibody, however, so it is quite possible that the 
protein decreased by treatment with DHEA is not cdc2. 
Although our data are limited, DHEA appears to have some effects on the 
expression of proteins involved in the control of the cell cycle. These changes could be 
involved in the modulation of AFB p-inititated hepatocarcingenesis by DHEA. In addition, 
the epigenetic modulation of p53 and other tumor suppressor or protooncogenes could be 
involved in the carcinogenesis of many nongenotoxic carcinogens. 152 
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ABSTRACT 
Dehydroepiandrosterone (DHEA) and its sulfate conjugate are the major circulating 
steroids in human plasma. Low levels of these adrenal androgens are associated with a 
number of human diseases including certain cancers. In animal studies, DHEA has been 
shown to be chemopreventive towards both spontaneous and chemically induced cancer. 
In contrast to these protective properties, however DHEA is a also a peroxisome 
proliferator. Like other peroxisome proliferators, DHEA is a hepatocarcinogen in rats, a 
species highly sensitive to peroxisome proliferation. DHEA, however, is also carcinogenic 
in rainbow trout; a species which is relatively insensitive to peroxisome proliferation. This 
study examines the effects of DHEA on N-methyl-N-nitro-nitrosoguanidine (MNNG) 
initiated carcinogenesis in trout. Trout fry were given a 30 min water bath exposure to 35 
ppm MNNG, a level producing primarily stomach, kidney, and swim bladder tumors. 
Fish were then fed diets containing 0, 55, 111, 222, 444, or 888 ppm DHEA for 7 
months. Post-initiation treatment with DHEA increased liver tumor incidence, multiplicity, 
and size in a dose dependent manner. Liver tumor incidence ranged from 1% in MNNG-
initiated controls to 99% in initiated trout treated with 888 ppm DHEA (tumor incidence in 
sham-initiated trout fed this level of DHEA was 37%). Kidney tumor incidence was also 
enhanced 2- and 4-fold over initiated controls by 111 and 888 ppm DHEA, respectively. 
In contrast, the number of stomach and swim bladder tumors were reduced by DHEA 
treatment. This study demonstrates differential effects of DHEA on MNNG-initiated 
carcinogenesis in liver, kidney, stomach, and swim bladder. 157 
INTRODUCTION
 
The hormones dehydroepiandrosterone (DHEA) and dehydroepiandrosterone 
sulfate (DHEAS) are secreted in large quantities from the human adrenal gland. The 
highest serum levels of DHEAS occur in early adulthood, then decline with age to about 
10-20% of maximum (1), leading to interest in the possibility that the loss of DHEA could 
be associated with some of the adverse changes occurring as people age (2). In humans, 
low levels of DHEA or DHEAS have been associated with cardiovascular disease in men, 
Alzheimer's disease, HIV, breast cancer, stomach cancer, bladder cancer, and lung cancer 
(3-8). In animal models, DHEA is chemoprotective towards a wide variety of disease 
conditions including atherosclerosis, diabetes, obesity, autoimmune disorders, and cancer 
(2, 9-13). Human clinical trials have been conducted, or are underway for the use of 
DHEA in the treatment of obesity, aging, cancer, diabetes, Alzeheimer's disease, multiple 
sclerosis, HIV, and lupus (9, 14, 15). 
DHEA, however, has a number of adverse effects. DHEA is a precursor for 
androgens and estrogens and, in human clinical trials has been shown to increase androgen 
levels in female subjects (16, 17). DHEA is also a carcinogen in laboratory animals (18, 
19). The hepatocarcinogenicity of DHEA in rats has been attributed to its properties as a 
peroxisome proliferator (20, 21), however we have also demonstrated that DHEA is both a 
complete carcinogen and a potent enhancer of AFB1 hepatocarcinogenesis in rainbow trout 
(19), a species which resembles humans in being relatively insensitive to peroxisome 
proliferation (22, 23). In trout, the hepatocarcinogenicity of DHEA appears to be due to its 
role as a steroid precursor rather than as a peroxisome proliferator (24). Conversion of 
DHEA into androgens and estrogens is probably also involved in other tumor enhancing 
effects of this compound including stimulation of growth of the R3327 Dunning implanted 
prostate carcinoma in rats (25), enhancement of pancreatic carcinogenesis in azaserine 158 
initiated rats (26); and induction of ovarian granulosa cell tumors in the genetically 
susceptible SWXJ-9 mice (27). 
In view of DHEA's dual role as a tumor modulator, we felt it would be of interest 
to compare the effects of this compound on carcinogenesis of multiple organs initiated 
simultaneously in a single species. 159 
MATERIALS AND METHODS 
Chemicals 
AFB 1, MNNG, and other reagents were purchased from Sigma Chemical 
Company (St. Louis, MO). 
Animals and treatment 
Mt. Shasta strain rainbow trout (Oncorhynchus mykiss) were raised at the Oregon 
State University Food Toxicology and Nutrition Laboratory. Animals were fed Oregon 
Test Diet (OTD), a casein based semipurified diet (28) and housed in circular tanks with 
continuously flowing 12-14° water and a 12 hour light-dark cycle. Three months after 
spawning 720 fry were given a 30 min bath exposure to 35 ppm MNNG. An equal 
number of trout were given a 30 min sham exposure to vehicle control (0.025% DMSO). 
Animals were fed control diet for an additional three months, then were assigned to 
experimental groups and given a modified OTD (100 mg Vit. E/kg dry diet) containing 0, 
55, 111, 222, 444, or 888 ppm DHEA. Each treatment group consisted of a single tank 
containing 120 trout. Diets were prepared by dissolving DHEA in the lipid component 
(salmon oil) and were stored at -20° C for up to three weeks. Once thawed, diets were 
refrigerated for no longer than 4 days prior to feeding. Animals were fed once per day 
(approximately 3-5% w/w of their body weight) and diet consumption recorded. Nine 
months after initiation, while still sexually immature, trout were killed by an overdose of 3­
aminobenzoic acid ethyl ester (MS-222). Livers, kidneys, stomachs, and swim bladders 
were examined for tumors, then were fixed in Bouin's solution. After fixation, livers were 
hand-sliced to look for internal tumors and verify previously identified tumors. Livers, 
stomachs, kidneys, and swim bladders were embedded in paraffin and saved for future 
histological examination. 160 
Statistical analysis
 
Tumor incidence was assessed using logistic regression and Fisher's exact test 
(two-tailed). The nonparametric Kruskal-Wallis test with chi-square approximation of p-
values was used to compare the average number of tumors per tumored animal. In groups 
with differences, pairwise comparisons were made by the Wilcoxon rank sum test. Body 
weights, liver weights, and tumor size were log transformed and compared by ANOVA 
followed by the LSD multiple range test for pairwise comparisons. Calculations were 
performed on the statistical package SAS, version 6.04 (SAS Institute, Cary, NC). 161 
RESULTS 
Animals treated with DHEA had lower body weights at terminal sacrifice compared 
to controls (Table 1). Food consumption was 3% lower in tanks of trout fed 888 ppm 
DHEA, however, all other treatment groups had caloric intake similar to controls (not 
shown). There was some mortality in trout treated with the highest level of DHEA. 
Eighteen percent of animals initiated with MNNG and fed 888 ppm DHEA died. Six 
percent of sham-initiated animals fed the same dose of DHEA died during the experiment. 
Mortality in all other experimental groups was 5_ 1%. Liver weights and liver somatic 
indexes (% of body weight made up by liver) both were increased in a dose dependent 
manner by DHEA treatment. 
Table 7.1. Effect of dietary DHEA on body weight, mortality, and liver weight 
Initiation  DHEA  Mort.  Final Body Wt.  Final Liver Wt.  Liver Somatic 
(g)b,c  (g)b,c (I)Pm)  (%)a  Index (%)b,c 
Sham  0  1  92.3 ± 2.4  0.49 ± 0.01  0.53 ± 0.01 
MNNG  0  1  95.4 ± 2.1  0.58 ± 0.02  0.60 ± 0.01 
Sham  55  0  71.1d + 1.8  0.49 ± 0.01  0.69d ± 0.01 
MNNG  55  1  81.1 ± 1.6  0.52 ± 0.01  0.64 ± 0.02 
Sham  111  0  72.7d ± 1.7  0.54d ± 0.01  0.74d ± 0.01 
MNNG  1 1 1  0  0.55 ± 0.02 77.0e ± 1.7  0.72e ± 0.01 
Sham  222  0  81.3 ± 1.8  0.64e ± 0.02  0.78d ± 0.01 
MNNG  222  1  78.3e ± 1.6  0.65d ± 0.02  0.83e ± 0.01 
Sham  444  1  79.6 ± 1.5  0.77e ± 0.02  0.97d ± 0.01 
MNNG  444  1  74.1e ± 2.0  0.77d ± 0.03  1.03e ± 0.02 
Sham  888  6  75.4d± 1.9  1.01e ± 0.03  1.34d ± 0.02 
MNNG  888  18  77.7e ± 2.0  1.51d ± 0.09  1.94e ± 0.01 
a  Mortality is % of animals that died while on experimental diets. 
b  + SE 
n = 100 for all groups except the MNNG-initiated fed 888 ppm DHEA, where n = 94. 
d  Significantly different from sham control at p < 0.05. 
e  Significantly different from MNNG control at p < 0.05. 
c 162 
In this experiment, as demonstrated previously (19), DHEA was a complete liver 
carcinogen in rainbow trout (Fig. 7.1). Tumor incidence (% of animals with tumors) 
increased in a dose-dependent manner, ranging from 1% of animals fed 55 ppm DHEA, up 
to 37% of animals fed 888 ppm DHEA. No liver tumors were observed in sham-initiated 
animals fed control diet. 
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Figure 7.1.  Liver tumor incidence and multiplicity in sham-initiated trout. * indicates 
significantly higher (p < 0.05) tumor incidence than sham-initiated controls. 
In addition to being a complete carcinogen, DHEA also dramatically enhanced 
MNNG-initiated hepatocarcinogenesis (Fig. 7.2). Tumor incidence increased with 
increasing doses of DHEA from 1% in the MNNG-initiated controls to 99% in MNNG-
initiated trout fed 888 ppm DHEA. The tumor size (in animals with tumors) ranged from 
0.5 mm in diameter in the single tumor observed in the MNNG initiated controls to an 163 
average of 3.5 ± 0.2 mm (± SE) in initiated animals fed 888 ppm DHEA. Tumor 
multiplicity increased in a dose-dependent manner with a single tumor per liver in the 
initiated controls and 55 ppm DHEA groups; and an average of 1.06 ± 0.06, 1.58 ± 0.14, 
2.87 ± 0.29, and 6.03 ± 0.44 in the 111, 222, 444, and 888 ppm DHEA-treated groups, 
respectively. 
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Figure 7.2.  Liver tumor incidence and multiplicity in MNNG-initiated trout. * indicates 
significantly higher (p < 0.05) tumor incidence than MNNG-initiated controls. # indicates 
significantly higher (p < 0.0005) tumor multiplicity than net highest treatment. 
One kidney tumor occurred in a sham-initiated trout fed 222 ppm DHEA for 30 
weeks. This observation, although not statistically significant, is of interest because renal 
tumors are extremely rare in untreated trout of this age. In MNNG-initiated trout, the 
observed kidney tumor incidence was higher in each of the DHEA-fed groups than the 164 
0 
controls, although only the 111 and 888 ppm DHEA treatments were significantly higher at 
the 0.05 level of significance (Fig. 7.3). 
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Figure 7.3.  Kidney tumor incidence and multiplicity in MNNG-initiated trout. * 
indicates significantly higher (p < 0.05) tumor incidence than MNNG-initiated controls. 
The p-value for tumor incidence in the 222 ppm DHEA group is 0.06. 
In contrast to DHEA's effects on liver and kidney carcinogenesis, DHEA appeared 
to offer some post-initiation protection towards stomach and swim bladder tumors. 
Although the stomach tumor incidence was not significantly different between DHEA-
treated animals and initiated controls, the total number of stomach tumors per treatment was 
significantly suppressed in all DHEA-treated groups (Fig. 7.4). 
DHEA treatment also reduced MNNG-initiated swim bladder carcinogenesis. 
Tumor incidence in DHEA-fed animals was significantly lower than initiated controls for all 
doses except the 444 ppm DHEA (Fig. 7.5). 165 
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Figure 7.4.  Number of stomach tumors in MNNG-initiated trout. * indicates 
significantly lower (p < 0.05) total number of tumors than MNNG-initiated controls (for 
statistical analysis, a maximum number of 6 tumors per stomach was assumed). 166 
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Figure 7.5.  Swim bladder tumor incidence in MNNG-initiated trout. * indicates 
significantly lower (p < 0.05) tumor incidence than in MNNG-initiated controls. 167 
DISCUSSION
 
Previous studies in our laboratory have found that DHEA is a potent enhancer of 
AFB 1- initiated hepatocarcinogenesis in trout. This study was designed to determine if 
DHEA enhancement of carcinogenesis was carcinogen or organ specific. Initiator specific 
promotion by the peroxisome proliferators clofibrate and WY 14,643 of the carcinogens N-
acetylamino-fluorine and diethylnitrosamine has recently been demonstrated (29). We 
selected MNNG as the initiator in the current study because, unlike AFB1, MNNG is a 
direct acting carcinogen and because a single exposure of trout fry to MNNG can produce 
tumors in four different organs. This provides a unique model for the study of modulation 
of carcinogenesis in more than one tissue without the need for multiple initiators or surgical 
procedures. In this experiment initiation conditions were selected that would produce 
predominantly stomach tumors, moderate numbers of kidney and swim bladder tumors, 
and a very low incidence of liver tumors. As predicted, the incidence of liver tumors was 
extremely low (1%) in the MNNG-initiated controls. Post-initiation treatment with DHEA 
dramatically enhanced liver tumor incidence to almost 100% in initiated animals fed 888 
ppm DHEA. Since sham-initiated trout produced tumors in only 37% of the animals, the 
combined effects of MNNG-initiation and DHEA treatment were clearly more than 
additive. DHEA may be acting by enhancing proliferation of initiated cells (30). 
In addition to dramatically enhancing liver carcinogenesis, treatment with DHEA 
also enhanced kidney tumor incidence in MNNG-initiated trout. There is one previous 
report of DHEA enhancement of renal carcinogenesis. An increased incidence of renal 
adenocarcinomas but not adenomas was found in dimethylnitrosamine-initiated rats treated 
with 6000 ppm DHEA for 26 weeks (31). Histopathology has not yet been performed on 
the tumors from our study, however tumors in the DHEA-treated animals tended to be 
larger (although not significantly) than in the initiated controls. In addition, the high 
mortality in the MNNG-initiated trout fed 888 ppm DHEA may have been due to renal 168 
carcinomas. Several of the animals from this treatment that died prior to sampling had 
large, externally visible kidney tumors. At our facility, approximately 30,000 trout are 
sampled annually. No spontaneous kidney tumors have been observed in at least the last 
three years. It is therefore of interest that in this study a single kidney tumor was found in 
a trout that was treated with 222 ppm DHEA. In addition, we have just completed a study 
in which the same levels of DHEA were fed to non initiated trout for 42 weeks. In this 
experiment, five out of 1000 DHEA-fed trout developed kidney tumors (Omer et al., 
unpublished data). 
There are a number of mechanisms through which DHEA could be acting to 
enhance carcinogenesis in the kidney. One possible mechanism is related to the renal 
toxicity of DHEA. In immature trout, treatment with DHEA causes induction of the 
estrogen inducible yolk protein vitellogenin (24, 30). This lipoprotein is normally secreted 
in response to B-estradiol in mature female trout and is rapidly taken up by the ovaries. In 
juvenile trout, vitellogenin secretion can be induced but the protein accumulates outside the 
ovaries (32). The high toxicity of B-estradiol in young trout has been attributed, in part, to 
kidney function impairment resulting from the accumulation of vitellogenin in the tubules, 
glomeruli, and sinusoids of the anterior kidney (32). We have observed similar renal 
toxicity in animals treated with high  444 ppm) doses of DHEA. The effects of DHEA 
on renal carcinogenesis could be the result of the accumulation of this protein, through 
cytotoxicity and proliferative cell growth. If so, this would be a mechanism specific to 
non-mammalian species with little relevance towards humans. 
However, the fact that enhancement of renal carcinogenesis has also been observed 
in rats (31) would indicate that this response is not unique to fish. Previous studies in our 
laboratory indicate that DHEA may have some genotoxicity. Although DHEA is negative 
in short-term mutagenicity assays (33-35), we detected Ki-ras mutations in about 30% of 
liver tumors in trout treated with DHEA (19). No Ki-ras mutations have been observed in 
spontaneous tumors in trout, however the number of tumors examined is quite small due to 169 
the low spontaneous incidence of liver tumors in trout. A direct effect of DHEA on DNA 
is, therefore, possible but requires further investigation. 
There is also the possibility that the renal effects could be related to DHEA's 
properties as a peroxisome proliferator. Although peroxisome proliferation is typically 
considered a hepatic response, peroxisomes were first described in the rodent kidney (36). 
Trout do not appear to respond in the same manner as rats and mice to peroxisome 
proliferators, however, no studies have examined peroxisome proliferation in extrahepatic 
tissues in trout. Only slight increases in hepatic peroxisomal 13- oxidation occur when trout 
are treated with DHEA, however significant decreases occur in peroxisomal catalase (24, 
30). This could result in the same sort of prooxidant condition that has been proposed as a 
possible mechanism of carcinogenicity of peroxisome proliferators in rodents (37). 
In contrast to its effects on liver and kidney, treatment of MNNG-initiated trout 
with DHEA provided protection towards stomach and swim bladder carcinogenesis. In 
humans, low plasma levels of DHEA and DHEAS have been associated with an increased 
risk of developing gastric cancer (8), however this is the first report of DHEA 
chemoprotection towards stomach cancer in an animal model. DHEA provided significant 
protection towards swim bladder carcinogenesis at doses as low as 55 ppm; one-fourth the 
dose which significantly enhanced liver carcinogenesis. Therefore, it appears that the 
cancer chemopreventive properties of DHEA are not limited to rodents. 
Despite its chemoprotective effects towards cancer, however, DHEA also has 
carcinogenic and tumor enhancing properties in multiple organs and multiple species (18, 
19, 25-27, 31). A high priority should be placed on determining if the carcinogenic effects 
of this compound pose a risk to human health, particularly since DHEA continues to be 
used in human chemoprevention studies. 170 
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SUMMARY 
The studies described in this thesis demonstrate that rainbow trout are extremely 
sensitive to the carcinogenicity and tumor enhancing properties of DHEA. DHEA is a 
complete carcinogen in trout at doses 20-fold lower than doses shown to be 
hepatocarcinogenic in rats. There are a number of possible explanations for this. Trout are 
highly sensitive to genotoxic carcinogens such as AFBi, possibly because of their low 
ability to repair bulky DNA adducts. In chapter 3, we show that tumors in DHEA treated 
trout have Ki-ras mutations. Therefore, DHEA may have some genotoxic properties. If 
so, this could explain the high sensitivity of trout to DHEA carcingenesis. Alternately, the 
tumor enhancing and carcinogenic effects of DHEA may be due to its steroid precursor 
effects. The trout carcingenesis model differs from rodent models in that trout tumor 
studies are completed prior to sexual maturation. The effects of DHEA as an estrogen or 
androgen may differ according to what sort of hormonal environment is present (1). In 
juvenile trout, the steroidal effects of DHEA may be particularly potent because they have 
such low endogenous hormone levels. It is also possible that a low dose of DHEA given 
to trout results in a greater bioavailable dose of DHEA than the same treatment in mammals 
because more of the compound is present in an active form. In humans, about 99% of 
DHEA exists as the sulfate conjugate, DHEAS. After short-term treatment of trout with 
dietary DHEA, serum levels of DHEA and the sulfate are approximately equal (chapter 4), 
possibly due to the low DHEA sulfotransferase activity in trout (2). The ratio of DHEA to 
DHEAS therefore, is much higher in trout than in humans. As a result, a higher proportion 
of DHEA is available for direct conversion into steroids. Some of the effects of DHEA, 
however appear to be due to the sulfate conjugate. For example, it has recently been 
demonstrated that DHEAS may be the active form for peroxisome proliferation (3). This 
could be part of the reason why trout are less susceptible to the peroxisome proliferating 
effects of DHEA as well, although it would not explain the low response of trout to other 175 
peroxisome proliferators. Another explanation for the high sensitivity of trout to DHEA 
could be due to a lack of chemoprotective effects to balance out the carcinogenic properties. 
DHEA carcinogenicity clearly occurs through a mechanism which can occur in trout. It is 
possible, however, that properties responsible for chemoprevention by DHEA in rodents, 
are not present in trout. Inhibition of G6PD may be involved in DHEA's anticancer effects 
(4-6). We did not observe any inhibition of G6PD in red blood cells of trout treated with 
DHEA or 8354 for two weeks (Chapter 5). In vivo studies in rodents, however have also 
failed to demonstrate inhibition of this enzyme (7). Further studies on the ability of DHEA 
to inhibit trout G6PD are necessary before we can conclude that this is a mechanism which 
does not occur in trout. Another possible mechanism of DHEA chemoprevention is 
through glutathione-S-transferase induction (8). Previous studies from our laboratory 
suggest that chemopreventive agents which act through the induction of GST are not 
effective in the trout model (9). Susceptibility to the carcinogenic, but not the 
chemopreventive effects of DHEA may account for the high sensitivity of trout to DHEA 
carcinogenesis. In trout initiated with MNNG, however, there is significant protection 
towards carcinogenesis of the stomach and swim bladder. 176 
SUGGESTIONS FOR FUTURE STUDY 
In this thesis, we present limited evidence that DHEA could be genotoxic. Many 
more spontaneous tumors must be examined for ras mutations, however before we can rule 
out the possiblity that DHEA is simply promoting tumors bearing spontaneous or pre­
existing ras mutations. In addition, DHEA's ability to bind to DNA should be thoroughly 
examined. In vitro incubation of rat microsomes with DHEA has been shown to produce 
DNA and protein-interacting species (10). We conducted one in vivo DNA binding 
experiment by injecting trout with [3H] DHEA (11),. In this study there was no evidence 
of DNA binding, however the dose used was many orders of magnitude lower than the 
carcinogenic dose. It would be extremely expensive to conduct this in vivo assay with 
carcinogenic doses of [3H] DHEA, however it would be relatively simple to determine if 
DHEA could be activated to DNA-binding intermediates by trout microsomes in vitro. To 
examine DHEA binding to DNA in vivo, the most appropriate method would probably be 
to examine DNA of DHEA-treated trout for DNA adducts using 32P-postlabeling. 
Studies in this thesis confirm reports that trout, like humans are relatively 
insensitive to peroxisome proliferation (12-16). An understanding of the mechanism of 
trout resistance to peroxisome proliferation is necessary, however, before we can conclude 
that trout are appropriate models for predicting human risk from these compounds. The 
difference in response between humans and rodents does not appear to be due to the lack of 
a functional peroxisome proliferator activated receptor (PPAR), as a human PPAR has been 
cloned that is able to activate the rat acyl CoA oxidase and rabbit CYP4A6 response 
elements (17). It should be fairly simple to determine if trout also have a functional PPAR. 
We have already established that trout have several proteins which cross react with a mouse 
PPARa antibody (unpublished data). The next step is to conduct gel mobility shift assays 
of trout nuclear extracts using a labeled peroxisome proliferator response element (PPRE) 
as a probe, followed by supershift assays using the PPARa antibody to confirm that the 177 
mobility shift is due to binding of a PPAR. The trout PPAR(s), if present, could be 
cloned, sequenced, and compared to Xenopus, human, and mouse PPARs. 
Another possible explanation for trout being weak responders to peroxisome 
proliferators could be related to the low levels of co-hydroxylation of fatty acids produced 
by trout P450s. Induction of P4504As (which catalyze co-hydroxylation of fatty acids) 
may be involved in the peroxisome proliferation response in rodents as induction of these 
enzymes occurs prior to the induction of 13-oxidation (18). 
Another area which should be further explored is the possiblity that mature trout 
might respond more like rodents to peroxisome proliferation than the juveniles used for the 
studies contained in this thesis. Testosterone has been shown to enhance the induction of 
peroxisomal b-oxidation in clofibrate-treated rats (19). It may be that in immature trout, 
induction of peroxisome proliferation is limited due to the lack of steroid hormones. We 
conducted a preliminary study to address this question by gavaging mature male trout with 
clofibrate or corn oil. In this study, trout still appeared to be weak responders to 
peroxisome proliferation, however there were some increases in liver wt. and 13-oxidation. 
A more effective dosing strategy might give more dramatic results. 
As discussed above, one explanation for the high sensitivity of trout to DHEA 
carcinogenesis is that trout have a limited ability to sulfate DHEA. Cloning and sequencing 
of the trout sulfotransferases would allow this hypothesis to be further examined by 
comparing trout, human, and rodent sulfotransferases. 
The MNNG experiment should be repeated using lower doses (possibly ranging 
from 10 to 100 ppm w/w). In the MNNG-modulation experiment (chapter 7), significant 
protection towards swim bladder and stomach carcingenesis was provided by doses as low 
as 55 ppm. This dose slightly (but not significantly) enhanced liver carcinogenesis, 
however it is possible that lower doses could provide significant protection towards 
stomach and swim bladder carcinogenesis without enhancing liver or kidney 
carcinogenesis. In rats, DHEA has recently been found to have chemoprotective effects 178 
towards MNU-induced breast cancer at 120 ppm, a dose which is less than 4% of the 
maximum tolerated dose (3000 ppm) (20). This is considerably lower than the doses 
which have been found to be hepatocarcinogenic in this species. It is possible that very 
low doses of DHEA in trout could be protective towards stomach and swim bladder 
carcingenesis without promoting hepatocarcinogenesis. 
A comparison of G6PD inhibition in vitro by DHEA (and the analog) in trout, rat, 
and human samples would help to establish if this mechanism of protection is present in 
trout. 179 
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